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Hepatocellular carcinoma (HCC) is one of the most frequently diagnosed and most
lethal cancers worldwide. In this thesis, I examined the role of microRNAs in HCC
using a systematic approach, combining gene and microRNA expression profiling with
in silico target prediction. I used mRNA and microRNA profiling data from tumors and
adjacent non-tumorous tissues of 100 HCC patients. Through integration of mRNA
and microRNA expression profiling with target prediction, I identified six relevant
microRNAs in HCC. Specifically, miR-21, miR-93, and miR-221 were up-regulated,
which was significantly associated with down-regulation of their predicted targets;
miR-26a, miR-122, and miR-130a were down-regulated, which was significantly
associated with up-regulation of their predicted targets.
I found that targets of relevant microRNAs are involved in critical cellular pro-
cesses associated with carcinogenesis. Targets of up-regulated relevant microRNAs
are enriched in metabolism and immune-system processes. Conversely, targets
of down-regulated microRNAs are involved in cell-cycle processes, specifically in
DNA replication and repair. Interestingly, relevant up-regulated microRNAs, down-
regulated respectively, modulate similar cellular processes through largely distinct
sets of targets. Therefore, these microRNAs collaboratively control the same path-
ways on different levels, which suggests system redundancy. Finally, through network
analysis of differentially expressed targets, I identified several genes that may act as
key molecules in these pathways.
xii
I associated expression of relevant microRNAs and their differentially expressed
targets with clinico-pathological parameters. FADS1 expression in non-tumorous
tissues showed significant association with overall and disease-free survival and
might therefore serve as a prognostic marker. In addition, I found several relevant
microRNAs or their differentially expressed targets to be significantly associated with
tumor stage, histological grade, AFP levels, cirrhosis, or tumor encapsulation. These
microRNAs and their dys-regulated targets might serve as independent diagnostic or
prognostic markers for HCC.
In summary, through a systematic approach, I demonstrated that microRNAs
coordinately modulate critical cellular pathways through distinct sets of target genes.
This is an important finding to be considered when designing therapeutic strategies
based on dys-regulated microRNAs in HCC. Moreover, I identified several relevant
microRNAs that potentially contribute to the pathogenesis of HCC. Their targets
are involved in processes related to metabolism and immune system response or
modulate the cell cycle. The results further point towards several key molecules,
which are potential candidates for further investigations. Finally, I found associations
between several dys-regulated microRNAs or their differentially expressed targets and
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Liver cancer is the sixth most common and the second most lethal cancer worldwide,
responsible for 745 000 annual deaths [1]. Hepatocellular carcinoma (HCC) is the
most common type of liver cancer and accounts for 70–85% of the total liver cancer
burden [2]. The poor outcome of liver cancer in general and of HCC specifically is
mainly due to the lack of symptoms at early stages and the unreliability of effective
treatments. The most effective treatment options are still partial liver resection or
liver transplantation [3]. However, these options are available in only a minority of
cases, when the cancer is diagnosed at early stages.
1.1.1 HCC etiology
HCC is associated with a variety of risk factors. One of the most important risk factors
is chronic hepatitis B virus (HBV) infection, with an estimated 350 million chronic
carriers worldwide [4]. The association of HCC with HBV explains the prevalence of
the disease in East and South-East Asia, and Sub-Saharan Africa, where chronic HBV
infection is endemic [2]. Another important risk factor is chronic hepatitis C virus
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(HCV) infection, with a prevalence of about 185 million [5]. Globally, 53% of HCCs
are attributable to HBV and 25% to HCV [6]. Other risk factors include exposure to
aflatoxin B1, alcohol-related cirrhosis, and non-alcoholic fatty liver disease. Despite
these well-established associations between risk factors and the disease, knowledge
of contributing risk factors does not translate into improvement in treatments.
1.1.2 HCC diagnosis, prognosis, and treatment options
Diagnosis
Diagnosis of HCC is difficult, primarily due the long time interval from viral in-
fection to hepato-carcinogenesis and the lack of symptoms at early stages. The
most widely used screening tools for patients at risk of developing HCC are serum
alpha-fetoprotein (AFP) levels and ultrasonography (US) [7]. However, the survival
benefit and the cost effectiveness of both AFP and US are debated due to their limited
sensitivity and specificity [8].
Staging and prognosis
The objective of a tumor staging system for HCC and other cancers is to assess the
prognosis of a patient, which allows for an appropriate selection of cancer therapy. In
addition, a standardized tumor staging system enables researchers to exchange data
regarding treatment and clinical outcome, which is essential for the development
of new therapies. The various liver cancer staging systems used in the clinics were
recently reviewed by Subramaniam et al. [9].
A frequently used staging system for HCC is the TNM staging algorithm [10].
TNM classifies tumors into four main subgroups (1 – 4), with stage III further divided
into three subroups (3A – 3C). The TNM classification is based on properties of the
primary tumor (T), and the presence or absence of regional lymph node metastases
(N) and/or distant metastases (M). In addition, the histological grade might be
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taken into consideration to assess the level of tissue differentiation. Four different
levels of differentiation are distinguished: Well differentiated (grade 1), moderately
differentiated (grade 2), poorly differentiated (grade 3), and undifferentiated tissue
(grade 4).
Treatment options
To date, the most effective treatment options are still partial liver resection or liver
transplantation [3]. However, only patients with early stage HCC are suitable for
surgical intervention. Patients with intermediate HCC may derive some benefit from
chemotherapy. Late stage patients will receive palliative treatment.
MicroRNAs as a novel and promising approach
Provided that it is difficult to diagnose HCC at early stages and that treatment options
for intermediate and late stage tumors are virtually unavailable, it is crucial to
develop better diagnostic markers as well as identify novel and effective therapeutic
strategies. The recent discovery of microRNAs and their involvement in HCC and
other cancers makes them promising candidates not only as diagnosis markers but
also as therapeutic targets [11].
1.2 MicroRNAs
1.2.1 MicroRNA background
MicroRNAs (miRNAs) are a class of short non-coding RNAs (⇠22bp) that play im-
portant roles in gene expression regulation through post-transcriptional repression.
They have been implicated in a variety of biological processes; these include immune
system response, differentiation, tumorigenesis and cell death [12], processes fre-
quently associated with cancer. Taken together, there is accumulating evidence that
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dys-regulated miRNAs contribute to cancer formation and/or progression through
modulation of critical cellular processes. They act as either tumor suppressor or
oncogenic miRNAs, depending on the cellular function of their targets [13].
To date, more than two thousand mature human miRNAs have been identified
(miRBase version 21). Using computational approaches, each of these miRNAs has
been predicted to regulate several hundred genes. In fact, it is estimated that over
60% of protein coding genes are regulated by miRNAs [14]. Therefore, miRNAs
constitute an important layer of post-transcriptional genetic programs.
Although the clinical applicability of miRNAs is not well-established yet, they
exhibit a set of properties advantageous for use in a clinical setting: (1) Their
relatively small number compared to gene transcripts makes miRNA expression
profiling less complicated; (2) The short nucleotide sequence length gives rise to a
better preservation; (3) Multiple genes in a pathway might potentially be targeted
through a single miRNA or miRNA family; (4) They are generally conserved in
evolution; and (5) Recently discovered circulating miRNAs in blood have the potential
to be harnessed as a non-invasive biomarkers.
1.2.2 MicroRNA biogenesis
Similar to protein coding genes, miRNAs are transcribed from DNA and exported
to the cytoplasm, where they interact with messenger RNAs (mRNAs). The miRNA
biogenesis process is illustrated in figure 1.1. MiRNAs are encoded either as inter-
genic long non-coding RNA (lncRNA) or within introns of host genes. MiRNAs are
transcribed from DNA by the RNA polimerase II/III as pri-miRNAs and processed
by the enzyme Drosha [15]. The resulting pre-miRNA has a stem-loop structure of
approximately 70bp [16], sometimes called a hairpin. The pre-miRNA is exported
from the nucleus to the cytoplasm by exportin-5. In the cytoplasm, it is processed into
two mature miRNAs by the enzyme Dicer [17]. Typically, only one mature miRNA
is retained and the other degraded. The retained mature miRNA is loaded onto
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RNA-induced silencing complex (RISC) together with Ago2 to mediate translational
repression or degradation through imperfect base pairing with the target mRNA’s 3’
untranslated region (3’-UTR).
Several miRNAs are encoded in multiple genomic locations. For example, hsa-
miR-7 is located on chromosome 9 (hsa-miR-7-1), on chromosome 15 (hsa-miR-7-2),
and on chromosome 19 (hsa-miR-7-3). MiRNA family members share a similar
sequence. The sequence similarity of these miRNAs gives rise to largely overlapping
sets of target genes, suggesting a similar function [18]. MiRNA clusters on the other
hand are groups of miRNAs which are encoded in close proximity of each other
and therefore, expressional dys-regulation often affects several members of a cluster.
For example, miR-221 and miR-222 form a miRNA cluster. They are encoded on
chromosome X, separated by approximately 1kb [19].
1.2.3 MicroRNA target prediction
Given their short sequence length and the non-perfect binding pattern with the
mRNA’s 3’-UTR, it is a challenge to reliably identify miRNA targets. It is believed that
miRNA target recognition in animals loosely follows a set of patterns that are critical
for target recognition [21–23]. These patterns are: (1) Perfect complementarity
(strong binding) at the 5’ end of the miRNA, usually at base positions 2–8. This region
is also referred to as the “seed” region; (2) Compensation for mismatches in the seed
region by conserved base pairing at the miRNA 3’ end; (3) Non-perfect binding of
the central region seems crucial for target regulation. This is sometimes referred
to as central bulge; (4) Optimal thermodynamic stability of the binding pattern.
The stability estimation is based on secondary structure prediction and generally
measured as free energy (DG); (5) The miRNA conservation in related species, such
as human, mouse, rat, and dog; (6) The occurrence of binding sites for multiple
miRNAs, for a collaborative regulation of gene expression; and (7) Preference for
the miRNA binding site location near the end of the 3’-UTR.
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Figure 1.1: MicroRNA biogenesis from DNA to RNA. Reprinted by permission from
Macmillan Publishers Ltd: Nature Cell Biology [20], copyright 2009.
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These target recognition patterns have led to the development of a number of in
silico miRNA target prediction algorithms. Different algorithms implement different
subsets of rules. Target predictions computed by these algorithms are generally
publicly available either through a query-interface or as a flat file or both. Some
algorithms or programs are can be downloaded and executed locally. Through input
parameters, target prediction can be customized to the users needs. Algorithms and
databases with support for target prediction in vertebrates are summarized in table
1.1. These algorithms implement all or a subset of the patterns outlined above. It
is important to note that because of the generally imperfect base paring between
miRNAs and their mRNA targets, prediction is noisy and therefore prone to false
positives. For that reason, target prediction tools generally overestimate the number
of targets actually regulated by a specific miRNA in a specific tissue or condition.
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Table 1.1: MiRNA target prediction databases (DBs) and programs available online, which provide support for vertebrates. DB refers to
pre-calculated target predictions which can be accessed through a website and/or downloaded as a flat file. Program indicates a target
prediction algorithm that is available for download and executable locally. Patterns for target prediction are: (1) Perfect complementarity at
5’ end (seed); (2) Perfect complementarity at 3’ end; (3) Central bulge; (4) Free energy; (5) Conservation across species; (6) Multiple binding
miRNA sites on the 3’-UTR; and (7) MiRNA binding sites near the end of the 3’-UTR.




program 1 2 3 4 5 6 7
miRanda DB+program http://www.microrna.org/ ÿ ÿ ÿ ÿ ÿ [24, 25]
MirTarget2
(miRDB) DB http://mirdb.org/miRDB/ ÿ ÿ ÿ ÿ [26]
TargetScan DB+program http://targetscan.org/ ÿ ÿ ÿ ÿ ÿ ÿ ÿ [27]
EIMMo3 DB http://www.mirz.unibas.ch/ElMMo3/ ÿ ÿ [28]
PicTar DB http://pictar.mdc-berlin.de/ ÿ ÿ ÿ ÿ [29]
DIANA-microT DB http://diana.cslab.ece.ntua.gr/microT/ ÿ ÿ ÿ ÿ ÿ ÿ [30]
MicroInspector DB http://bioinfo.uni-plovdiv.bg/microinspector/ ÿ ÿ ÿ [31]
RNA22 DB+program https://cm.jefferson.edu/rna22v2/ ÿ ÿ ÿ [32]
miRWalk DB http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ ÿ [33]
RNAhybrid DB+program http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/ ÿ ÿ ÿ [34, 35]
RepTar DB http://reptar.ekmd.huji.ac.il/ ÿ ÿ ÿ ÿ ÿ [36]
mirBase DB http://www.mirbase.org/ No target prediction [37]
miRNAMap DB http://mirnamap.mbc.nctu.edu.tw/ No target prediction [38]
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1.3 MicroRNAs and cancer
There is accumulating evidence that miRNAs play an integral part in gene regulation.
The human genome encodes for over 2000 distinct mature miRNAs, each of which
regulates the expression of several hundred genes. Each cell type likely has a specific
miRNA expression signature, dominated by a unique set of miRNAs, which regulates
gene expression in a tissue-specific manner. MiRNAs control a broad variety of biolog-
ical processes, such as cell growth and death [39], development and differentiation
[40], and metabolism [41]. In other words, miRNAs exhibit an extensive impact on
gene expression and consequentially the protein abundance in cells. Therefore, it is
not surprising that dys-regulation of miRNA expression has been implicated in the
pathogenesis of many cancers.
Typically, tumor suppressor miRNAs are down-regulated in cancer and their
targets are involved in promotion of tumor formation or progression. Oncogenic
miRNAs are up-regulated in cancer and their targets are involved in the control or
suppression of cancer-associated pathways. Alteration of miRNA expression can be
caused by various mechanisms. These mechanisms include alterations of genomic
loci with miRNAs, epigenetic silencing, or aberrant expression of transcription factors
that target specific miRNAs.
1.3.1 Early reports of microRNAs as cancer genes
The earliest report of miRNA involvement in cancer suggested that miR-15a and
miR-16-1 are down-regulated in chronic lymphocytic leukemia (CLL) [42]. Aberrant
expression of these miRNAs was attributed to frequent deletions on chromosome
13q, observed in ⇠70% of the cases. These findings suggested a role of miR-15
and miR-16 as tumor suppressors in CLL and highlighted the need for chromosomal
mapping of all miRNAs in the human genome. A follow-up study conducted by the
same group investigated the genomic location of known miRNAs and found that
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more than half of the miRNAs examined (98/186) are located in regions frequently
affected by non-random genomic alterations [43]. These findings strongly suggested
that miRNAs are involved in the pathogenesis of cancer.
Members of the miR-17-92 cluster were among the first miRNAs reported with
an oncogenic role [44]. MiRNAs in this cluster are transcribed from a region of DNA
that is frequently amplified in B-cell lymphomas [45]. As a results, over-expression
of members of this cluster could possibly lead to accelerated tumorigenesis, together
with MYC amplification in a B-cell lymphoma mouse model.
1.3.2 MicroRNAs as tumor suppressors
Many miRNAs have been attributed with a tumor suppressors role in healthy tissues.
Tumor suppressor miRNAs frequently dys-regulated in cancers are summarized in
table 1.2
In 2000, let-7 was the first human miRNA identified: it comprises of a cluster
of 13 highly conserved pre-miRNAs that gives rise to 10 distinct mature miRNAs,
the let-7 family [46, 47]. Their tumor suppressor function was first described by
Johnson et al. The authors also identified RAS, an oncogene frequently dys-regulated
in cancer, as a direct target of let-7 . HMGA2 is another target of let-7 , often highly
expressed in tumor compared to normal tissue [49], which promotes lung cancer
progression [50]. Over-expression of let-7 leads to a reduction of HMGA2 expression
levels in lung cancer cells [51].
ThemiR-15a–16-1 cluster is down-regulated in CLL and targets BCL2, an oncogene
involved in apoptosis inhibition [60]. Conversely, suppression of BCL2 expression by
these miRNAs in a leukaemia cell line model induces apoptosis. CCND1 and WNT3A
are other validated targets of miR-15a and miR-16-1 [62]. Up-regulation of CCND1
and WNT3A through miR-15a–16-1 knockdown results in stimulation of survival,
proliferation, and invasion in healthy prostate cells. Reconstitution of the miRNA
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Table 1.2: MiRNAs frequently dys-regulated in cancer. MiRNAs down-regulated in
cancer act as tumor suppressor (TS), whereas miRNAs up-regulated as oncogene
(OG). MiR-15a/16-1 acts as either TS or OG, depending on the cancer type.
MicroRNA Targets Function Cancer
let-7 cluster RAS, HMGA2,MYC TS
Breast [52], gastric [53], head and neck
[54], liver [55], lymphoma [56, 57],
lung [51], prostate [58], skin [59]
BCL2, CCND1,
WNT3A TS




OG Cervical [64], head and neck [65],lymphoma [57], renal [66]
miR-17–92 cluster MYC, TSP1, CTGF OG Colorectal [67], liver [68], lung [69],lymphoma [44], pancreatic [70]
miR-21 PDCD4, PTEN OG
Breast [71], colorectal [72], gastric [73],
brain [74], liver [75], lung [76], head





Breast [78], gastric [79], liver [80],
ovarian [81], prostate [82],
cholangiocarcinoma [83]
miR-26a EZH2, CCND2,CCNE2, MTDH TS
Breast [84], liver [61], lymphoma [57,
85], head and neck [86], thyroid [87]
miR-34a/b/c BCL2, CCNE2,CDK4, MET TS
Breast [88], CLL [89], colon [90], lung
[91], liver [61], lymphoma [57],





Bladder [94], breast [95], gastric [96],







Bladder [101], breast [52], cervical
[64], colon [102], colorectal [103],
gastric [104], head and neck [54], liver
[105], lung [106], prostate [58]
miR-155 TP53INP1, MSH2,MSH6, MLH1 OG
Breast [52], colorectal [107], liver







Breast [111], glioblastoma [112], liver
[113, 114], lung [114], pancreatic [77],
prostate [115], skin [116], thyroid
[117]
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expression in a prostate cancer mouse model results in growth arrest, apoptosis, and
regression of the tumor.
Interestingly, the miR-15a–16-1 has a dual function and acts as oncogene in other
types of malignant tissues, such as head and neck [65], renal [66], or cervical [64]
cancers. This adds an additional layer of complexity as miRNAs can either act as
tumor suppressors or oncogenes, depending not only on the tissue type (malignant
or non-malignant), but also on the cell type.
MYC, an oncogene frequently mutated [118] and/or amplified [119] in cancer,
represses the function of the tumor suppressor miR-26a in lymphoma [85]. Con-
versely, induced expression of miR-26a in Burkitt’s lymphoma cell lines leads to
down-regulation of EZH2 and consequentially a decrease in cell proliferation. MiR-
26a is down-regulated in a number of solid tumors such as breast, liver, head and
neck, or thyroid (1.2). In normal liver tissue, miR-26a is expressed at high levels
and induces cell-cycle arrest through post-transcriptional regulation of CCND2 and
CCNE2 [61]. Similarly, over-expression ofmiR-26a in thyroid derived cell lines results
in inhibition of cell growth [87].
The miR-34 family is comprises three miRNAs, namely miR-34a, miR-34b, and
miR-34c. The miR-34 loci contains a p53 response element through which p53
activates transcription in response to DNA damage or oncogenic stress [120]. Ectopic
expression of the miR-34 family induces cell-cycle arrest in the G1 phase and miR-34-
b/c inhibit proliferation and colony formation [121–123]. MiR-34 further induces
apoptosis upon over-expression in neuroblastoma cells [124]. Taken together, the
miR-34 family of miRNAs acts as a tumor suppressor and regulates important cellular
processes, frequently dys-regulated in cancer.
The miR-141–200 cluster, comprising miR-141 and miR-200a, miR-200b, and
miR-200c, is involved in the control of epithelial to mesenchymal transition (EMT)
process through regulation of ZEB genes [125, 126]. Expression of ZEB1 and ZEB2
stimulates EMT through repression of E-cadherin [127]. Furthermore, low expression
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of miR-141–200, frequently observed in cancer [96, 98], is associated with poor
outcome [99], suggesting a tumor suppressor role for miR-141–200.
Together with p53 andMYC,miR-145 is part of a negative feedback loop, involved
in the regulation of differentiation, cell cycle, and apoptosis [128]. Expression of
miR-145 is induced by p53 through a response element in the miRNA promoter.
Furthermore, miR-145 inhibits MYC expression through post-transcriptional regu-
lation. In return, MYC activates p53 in various ways [129]. Interestingly, miR-145
also targets the pluripotency factors OCT4, SOX2, and KLF4. As a results, miR-145
inhibits self-renewal and induces differentiation of human embryonic stem cells
[130]. This suggests that inactivation of p53 and, as a consequence a decrease in
miR-145 expression, promote the expansion of cancer stem cells [131].
1.3.3 MicroRNAs as oncogenes
Over-expression of miRNAs has been reported in a variety of tumors and there
is accumulating evidence that some of these aberrantly expressed miRNA possess
oncogenic functions. The aforementioned miR-17–92 cluster is a well characterized
oncogene family comprised of miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and
miR-92 [132]. Similar to B-cell lymphoma [44], miRNAs of the miR-17–92 cluster
are over-expressed in lung cancer cell lines, attributed to a significant increase in
copy number of the miRNA cluster coding region on chromosome 13 [69]. The
miR-17–92 cluster is involved in cancer-related pathways such as angiogenesis and
apoptosis. The anti-angiogenic factors CTGF and TSP1 are targets of miR-18 and miR-
19, suggesting thatMYC-induced over-expression ofmiR-17–92 activates angiogenesis
[133]. Other important validated targets of the miR-17–92 cluster are PTEN, an
inhibitor of AKT signaling, and pro-apoptotic gene BIM [134].
ThemiR-25–106b cluster is frequently studied together with themiR-17–92 cluster
of miRNAs. Although they reside in different genomic locations (chromosome 7 and
chromosome X), the two clusters were found to be paralogs. Subsets of miRNAs in
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each cluster are homologs, miRNAs with very similar sequences (reviewed in [135]).
The miR-25–106b cluster comprises of miR-25, miR-93, and miR-106b, which reside
within intron 13 of MCM7. Activation of the transcription factor E2F1 leads to over-
expression of MCM7 and as a results, up-regulation of members of the miR-25–106b
cluster in gastric cancer [79]. miR-106b and miR-93 impair cell cycle arrest and
apoptosis through regulation of CDKN1A and BIM, associated with TGF  resistance.
The miR-25–106b pathway has been reported dys-regulated in other tumors, such as
breast [78], gastric [79], liver [80], ovarian [81], and prostate [82] cancers.
MiR-21 is one of the most well studied oncogenic miRNAs. RAS-induced over-
expression of miR-21 leads to an alteration of its regulatory activity in a myriad
of solid tumors [76, 136] (table 1.2). The metastasis suppressor gene PDCD4 is a
target of miR-21 in breast [71], colorectal [72] and liver [137] cancers, and as a
consequence, miR-21 promotes invasion and metastasis. PTEN is another validated
target of miR-21. Post-transcriptional regulation of PTEN stimulates tumor growth
and invasion in liver and lung cancer [75, 138].
MiR-155 is up-regulated in Burkitt’s [110], B cell [139], and Hodgkin’s [140]
lymphomas. MiR-155 is further up-regulated in thyroid, breast, colon, cervical, lung
cancer, and pancreatic ductal adenocarcinoma, reviewed in [141]. In pancreatic
cancer, miR-155 controls the stress-induced, pro-apoptotic gene TP53INP1 [142].
In colorectal cancer, over-expression of miR-155 has been shown to correlate with
the expression of mismatch repair (MMR) genes MSH2 and MLH1, associated with
repression of MMR and genomic instability [107].
MiR-221 and miR-222 are encoded in tandem on chromosome X, with the same
seed sequence. As a consequence, the vast majority of predicted targets are shared
between the two miRNAs (80–90% as predicted by MiRanda target prediction).
Therefore, these two miRNAs are frequently reported dys-regulated together, in
the same tumor. Both are consistently over-expressed in cancer and regulate cell
cycle inhibitors CDKN1B and CDKN1C, associated with activation of cellular growth
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and proliferation [113, 115, 117]. Additionally, miR-221 and miR-222 target tumor
suppressor genes PTEN and TIMP3 resulting in resistance to TNF-induced apoptosis
[114]. In addition, it enhances cellular migration through AKT signaling pathway
activation.
1.3.4 MicroRNAs as therapeutic targets
There is strong evidence that specific miRNAs regulate key cellular pathways, which,
when dys-regulated, contribute to the pathogenesis of various cancers. Therefore,
miRNAs could be considered as potentially effective targets for therapeutic interven-
tion in cancer treatment. Possible therapeutic applications would either selectively
induce over-expression, bind to the transcript, or inhibit expression of the miRNA in
malignant cells through other means. Different approaches have been proposed.
For miRNAs which exhibit a gain-of-expression in cancer, a possible therapy
strategy might be to administer anti-miRNA oligonucleotides (AMOs), which are
single-stranded nucleotide sequences with direct complementarity to the miRNA
sequence [143]. AntagomiRs are similar to AMOs, but chemically modified to increase
their stability by minimizing degradation [144]. A third approach, called locked
nucleic acids (LNAs), improves hybridization affinity towards complementary single-
stranded RNA and has successfully been applied to silence specific miRNAs [145, 146].
Finally, miRNA sponges are transgenes expressed in cells which contain multiple
tandem-binding sites [147]. These inhibitors, expressed from strong promoters,
compete with target mRNA. Although miRNA sponges are not suitable for therapeutic
applications, they are still a valuable tool and have been successfully used to inhibit
miRNA expression in vitro [147] and in vivo [148].
Tumor suppressor miRNAs that frequently exhibit a loss-of-function phenotype
in cancer are summarized in table 1.2. A possible approach to re-establish their
expression is called miRNA mimics. MiRNA mimics are synthetic single or double-
stranded short sequences that mimic a specific miRNA [149] — the short sequences
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are chemically modified for efficiency and stability purposes. Direct tumoral injec-
tions of miR-29 mimics stimulated apoptosis and decreased tumorigenesis in HCC
and leukaemia mouse models [150, 151]. Another strategy to re-establish miRNA
expression in tumor tissues is through adenovirus-associated vectors (AAVs) [152].
Such vectors efficiently transduce target cells, an important advantage over other
miRNA delivery methods. AAVs have successfully been applied to increase miRNA
expression in a liver cancer mouse model [61].
The methods described are successfully applied to modulate miRNA expression
in vitro and in vivo, and some were tested in clinical trials [153]. Nevertheless, there
are challenges associated with most methods, such as efficient tissue-specific delivery,
off-target effects, as well as safety [154]. These challenges have to be considered
carefully when designing miRNA-based targeted therapies.
1.4 MicroRNAs in HCC
In HCC, as in other cancers, there is an increasing number of studies that asso-
ciate miRNAs with the pathogenesis of the disease. Several miRNAs frequently
dys-regulated in various cancers are consistently up- or down-regulated in HCC, such
as miR-21, miR-26a, or miR-221/222 (table 1.2). Other miRNAs are more specific to
HCC or a smaller group of cancers, such as miR-155, miR-199a, or miR-224. MiR-122
is a liver-specific miRNA, expressed at high levels in the liver, but undetectable in
other tissues [155]. A list of dys-regulated miRNAs, tumor suppressor and oncogenes,
is provided in tables 1.3, 1.4, and 1.5, along with their targets and the relevant
biological functions they modulated.
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Table 1.3: Tumor suppressor microRNAs and their targets in HCC.
miRNA




miR-1 EDN1,FOXP1,MET,HDAC4 Viability, proliferation, growth [166, 167]
miR-7a PIK3CD,MTOR,RPS6KB1 Growth, metastasis [168]
miR-15a/16 CCND1 HBV-specific, growth,proliferation, viability [169, 170]
miR-15b BCL2L2 Recurrence, viability [171]
miR-26a/b CCND2,CCNE1,CCNE2,IL6,CDK6,ESR1 Viability, proliferation, metastasis [61, 172–175]
miR-30a VIM,MMP3 Viability, proliferation, metastasis [176]
miR-99a/100 PLK1,IGF1R,MTOR Poor prognosis, growth,proliferation [177–179]
miR-101 MCL1,DNMT3A,FOS,RAB5A,STMN1,ATG4D,SOX9
Poor prognosis, viability,

















metastasis [75, 164, 204–211]
miR-138 CCND3 Growth, proliferation [212, 213]
miR-139 ROCK2,FOS Metastasis [164, 180, 214, 215]
miR-140 TGFBR1,FGF9,DNMT1 Poor prognosis, growth,metastasis, carcinogenesis [216, 217]









miR-152 DNMT1 HBV-specific, methylation [230]
miR-193b CCND1,ETS1 Proliferation, metastasis [231]
miR-195 CHUK,TAB3,VEGF,VAV2,CDC42,CCND1,CDK6,E2F3
Angiogenesis, proliferation,
metastasis [156, 204, 232–234]
miR-198 MET Growth, metastasis [235, 236]
miR-199a-3p MTOR,MET,PAK4,CD44 HCV replication, proliferation,viability
[75, 156, 180, 204,
237–241]
miR-199a-5p DDR1,CHC Drug resistance, invasion [213, 242, 243]
miR-199b HIF1A Poor prognosis, growth [244]
miR-203 ABCE1,BIRC5 Poor prognosis, profliferation [189, 202, 245, 246]
miR-214 FGFR1,CTNNB1,HDGF, EZH2 Poor prognosis, angiogenesis,viability, growth, invasion
[156, 180, 241,
247–250]
miR-219 GPC3,SMC4 Carcinogenesis, metastasis [251, 252]
miR-223 STMN1 Carcinogenesis [156, 180, 188, 194]
miR-302b AKT2,EGFR Proliferation [253, 254]
miR-363 USP28,S1PR1 Proliferation [229, 255]
miR-375 MTDH,YAP,ATG7 Viability, growth, proliferation,invasion [256, 257]
miR-376a PIK3R1 Proliferation, viability [258]
miR-429 RAB18 Proliferation, metabolism [259]
miR-449 MET Proliferation, viability [260]
miR-450a DNMT3a Proliferation [261]
miR-520b/e MEKK2,CCND1,NIK Growth, proliferation [262–264]
miR-612 AKT2 EMT, metastasis [265, 266]
miR-637 LIF Growth, viability [267]
miR-1271 GPC3 Growth [268]
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1.4.1 Tumor suppressor microRNAs in HCC
Cell proliferation and tumor growth
Several studies associated miRNAs with cell proliferation and tumor growth by
means of direct interaction with positive and negative cell cycle regulators. Kota
et al. showed that miR-26a acts as a cell cycle regulator through induction of G1 cell
cycle arrest [61]. This is achieved by direct regulation of CCND2 and CCNE2, two
important factors in cell cycle transition through G1/S phase [269]. Similarly, miR-
195 controls expression of CCND1 and CDK6, two other factors that promote G1/S
transition [234]. MiR-138 is also involved in the control of growth and proliferation
by targeting yet another positive regulator of the cell cycle, CCND3 [212]. The
expression of the prominent tumor suppressor miR-122 is inversely correlated with
the expression of CCNG1, a gene frequently up-regulated in cancer and involved
in tumor growth [156]. In addition, miR-122 targets other cell cycle progression
genes, such as SRF and IGF1R [191, 270]. Moreover, miR-122 is highly expressed
during liver development. Through knockdown and over-expression of miR-122, it
has been shown that miR-122 regulates CUTL1 expression to maintain the balance
between proliferation and differentiation in hepatocytes, two processes often found
dys-regulated in HCC [198].
Migration and invasion (metastasis)
Recent studies have implicated miRNAs with migration and invasion, cellular pro-
cesses thought to be critical for metastasis formation. The mesenchymal epithelial
transition factor (MET), a promoter of metastasis, is frequently over-expressed in
HCC [271]. Several miRNAs silenced in HCC, such as miR-1 [167], miR-34a [272],
miR-148a [228], miR-198 [235], and miR-199a-3p [237], were shown to directly
control the expression of MET. MiR-199a-3p further regulates MTOR, which is asso-
ciated with cell cycle arrest and reduced invasive capabilities [237]. MiR-122 was
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also attributed with anti-metastatic properties through the regulation of ADAM10
and ADAM17. These genes are involved in various processes, such as cell adhesion,
invasion, and migration [191, 196]. Moreover, loss of expression of miR-139 leads
to an increase in invasive ability in vitro and HCC metastasis in vivo through dys-
regulation of its targets, ROCK2 and FOS [214, 215]. In addition, ROCK2 and the
EZH2 oncogene are direct targets ofmiR-124 [203]. More recently, an anti-metastatic
role of miR-26a was described and high miR-26a expression was found to correlate
with better prognosis [173].
Cell viability and apoptosis
Tumor suppressor miRNAs frequently control genes with an anti-apoptotic role. MiR-
125b targets BCL2 and BCL2L2, members of the anti-apoptotic BCL-2 protein family
[209, 210]. BCL2L1, another BCL-2 gene, is controlled by the let-7 family of miRNAs
[55]. Over-expression of let-7c or let-7g induces a decrease in BCL2L1 expression
in HepG2 and Huh-7 cells. Notably, let-7c over-expression led to a pro-apoptotic
effect in hepatoma cells upon treatment with Sorafenib, a chemotherapeutic agent
that targets BCL-2 family member MCL1. Expression of BCL2 and MCL1 is further
controlled by miR-29a, and low expression of miR-29a correlates with poor prognosis
[150]. Finally, miR-122 exerts its tumor suppressor role by controling the same
anti-apoptotic protein family. Over-expression of miR-122 decreases BCL2L2 protein
levels, which results in a reduced cell viability through induction of caspase CASP3
expression in Hep3B and HepG2 cells [195]. Moreover, miR-122 over-expression
increased sensitivity to apoptosis in HCC-derived cell lines upon treatment with
chemotherapeutic agent Doxorubicin [273].
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Table 1.4: Oncogenic microRNAs and their targets in HCC.
miRNA
cluster/family Targets Characteristics References
miR-10a/b EPHA4,CADM1 Poor prognosis, EMT, metastasis [189, 274, 275]
miR-17–92 HSP27 Migration [68, 276–278]
miR-18a ESR1 Proliferation [80, 180, 204, 279]
miR-21 PTEN,PDCD4,RECK,RHOB, PELI1 Growth, proliferation, viability,metastasis
[68, 75, 180, 189,
192, 194, 280–282]
miR-23a PPARGC1A,G6PC,TOP1 Metabolism, chemosensitivity [283, 284]
miR-25–106b BIM,E2F1,APC,RHOA,RHOC Growth, proliferation, migration,EMT [80, 285, 286]
miR-30d GNAI2 Metastasis [287]
miR-130b TP53INP1 Growth, self-renewal [180, 288]
miR-135a MTSS1 Metastasis [180, 289]
miR-143 FNDC3B Metastasis [290]
miR-151 ARHGDIA Metastasis [291, 292]
miR-155 CEBPB,APC,SOX6,SOCS1 Poor prognosis, invasion, growth,proliferation, viability
[108, 156, 192,
293–295]
miR-181b/d CDX2,GATA6,NLK,TIMP3 Growth, viability, metastasis [296–298]
miR-182–183 AKAP12,PDCD4,MTSS1 Poor prognosis, viability,metastasis [299–301]
miR-186 AKAP12 Carcinogenesis [299]
miR-210 VMP1,AIFM3 Proliferation, viability, metastasis [75, 302, 303]




[75, 113, 114, 156,
180, 188, 189, 192,
194, 307–311]
miR-224 API5,SMAD4 Proliferation, metastasis [189, 204, 312–315]
miR-301a MEOX2 Proliferation, metastasis [180, 316]
miR-373 PPP6C Proliferation [75, 317]
miR-423 CDKN1A Proliferation, growth [318]
miR-483 SOCS3 Proliferation [319]
miR-485-3p MAT1A Growth, metastasis [320]
miR-490-3p ERGIC3 Proliferation, EMT, metastasis [321]
miR-494 MCC Carcinogenesis [322]
miR-495 MAT1A Growth, metastasis [320]
miR-517a–519d CDKN1A,PTEN,AKT3, TIMP2 Proliferation, viability, metastasis [323, 324]
miR-550a CPEB4 Metastasis [325]
miR-590 TGFBR2 Proliferation, invasion [326]
miR-602 RASSF1A Proliferation, viability [327]
miR-615 IGF2 Growth, migration [328]
miR-657 TLE1 Carcinogenesis [329]
miR-664 MAT1A Growth, metastasis [320]
miR-1246 CADM1 Metastasis [330]
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1.4.2 Oncogenic microRNAs in HCC
Cell proliferation and tumor growth
MiR-21 and miR-221 are frequently and consistently reported to be over-expressed
in HCC. They have been implicated in the promotion of cell proliferation and growth.
Their most prominent target is PTEN, a tumor suppressor associated with the regula-
tion of cell growth and spread [75, 114]. Inhibition of miR-21 increases expression
of PTEN in HCC-derived cell lines, and decreases their proliferation and metastatic
potential. Moreover, miR-221 directly targets cyclin-dependent kinase inhibitors
(CDKIs), CDKN1B and CDKN1C, to promote tumor growth [113]. Down-regulation
of these CDKIs increases the number of cells in S-phase. MiR-221 further modulates
tumor growth through down-regulation of DDIT4, a gene implicated in the mTOR
pathway [307]. More recently, miR-373 and miR-519d have also been involved in
the alteration of cell proliferation and growth [317, 324]. MiR-373 blocks expression
of PPP6C, a cell cycle regulator that controls G1/S phase transition. MiR-519d targets
PTEN and CDKN1A, another CDKI.
Migration and invasion (metastasis)
Oncogene miR-21 is consistently up-regulated in many solid tumors (table 1.2). As
previously mentioned, miR-21 directly inhibits expression of tumor suppressor PTEN
to modulate critical cellular pathways such as proliferation, invasion, and migration
[75]. MiR-221 and miR-222 have been described to act in a similar fashion through
regulation of PTEN and PPP2R2A, which leads to an activation of the AKT pathway
and consequentially enhances the metastatic potential of HCC cells [114, 309].
Moreover, the miR-221–222 cluster controls the expression of TIMP3, an inhibitor
of metallopeptidases [114]. Breakdown of the extracellular matrix, for example
through metallopeptidases, is critical for the induction of the metastatic process.
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Similarly, TGF- -induced up-regulation of miR-181b stimulates the expression of
metallopeptidases, MMP2 and MMP9, through repression of TIMP3 [297].
Several other miRNAs have been involved in the stimulation of pro-metastatic
pathways. Firstly, over-expression of miR-17 promotes migration and proliferation
of HCC cells through activation of p38-MAPK signaling and subsequent HSP27
phosphorylation [276]. In another study that investigated HBV-related HCC, NF-
B induced over-expression of miR-143 was shown to promote tumor metastasis
through direct repression of FNDC3B [290]. Moreover, miR-151 is located in the
frequently amplified chromosomal region 8q24.3 and expressed together with its
host gene FAK. Aberrant expression of miR-151 and FAK is associated with enhanced
migration and invasion abilities of HCC cells in vitro and in vivo [292]. More recently,
miR-490-3p was reported as up-regulated in HCC and involved in the promotion of
cell proliferation, migration, and invasion through down-regulation of ERGIC3 [321].
Cell viability and apoptosis
It was previously discussed that tumor suppressor miRNAs promote apoptosis through
targeting anti-apoptotic genes of the BCL-2 family, such as BCL2, BCL2L1, or BCL2L2.
Conversely, oncogenic miRNAs stimulate carcinogenesis through regulation of pro-
apoptotic member of the BCL-2 family. Expression of oncogenic miR-221 correlated
with BMF and activated caspase-3 (CASP3) in HCC tissues [308], while silencing
of miR-221 in cell lines up-regulated BMF and induced apoptosis. BIM, also a pro-
apoptotic BCL-2 gene, is targeted bymiR-25, a member of the oncogenicmiR-106b–25
cluster [80]. Furthermore, oncogenic miRNAs exert their pro-apoptotic function by
targeting other genes apart from the BCL-2 family. For example, miR-183 inhibits
TGF- 1-induced apoptosis by controlling PDCD4 expression [300]. PDCD4 was
further identified as a target of miR-21 [281]. As previously mentioned, the miR-
221–222 cluster targets PTEN and TIMP3 [114]. Regulation of these two tumor
suppressors induces TNF-related apoptosis-inducing ligand (TRAIL) resistance and
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enhances cellular migration through the AKT signaling pathway. The authors further
showed that the MET oncogene activates expression of miR-221–222 through the
JUN transcription factor.
1.4.3 MicroRNAswith both tumor suppressor and oncogenic func-
tion in HCC
Several miRNAs have been reported to exert oncogenic and tumor suppressor roles
in HCC. These miRNAs and their functions are summarized in table 1.5. Different
underlying diseases might explain why some of these miRNAs are reported dys-
regulated in different directions. For example, miR-29a is down-regulated in HCCs
and targets anti-apoptotic factors BCL2 and MCL1 in HepG2 [150], a cell line where
hepatitis B surface antigenes are undetectable. However, in HBV-induced HCCs, miR-
29a is over-expressed and high expression is associated with early recurrence and
poor overall survival [331]. In other cases, the underlying cause of the controversial
findings are not evident from the respective reports. For example, miR-200b was
found up- and down-regulated in methyl-deficient diet induced HCC in a rodent
model [332, 333].
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Table 1.5: MiRNAs with an oncogenic (OG) and tumor suppressor (TS) role in HCC.
miRNA
cluster/family TS/OG Targets Characteristics References
miR-22
















growth, metastasis [272, 332, 343, 344]
OG NASH/NAFLD specific [75, 333]
miR-130a
TS ESR1 Poor prognosis [156, 327, 345, 346]
OG RUNX3 Drug resistance [187, 347]
miR-200a/b/c
TS ZFHX1B,CDH1,HDAC4 Proliferation, migration
[164, 180, 189, 194,
204, 332, 348, 349]
OG KEAP1,ZEB1 Growth, proliferation [333, 350]
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1.5 Objectives of this thesis
In this thesis, I sought to accomplish three main objectives to better characterize the
role of miRNAs in HCC. These objectives are outlined below:
1. To systematically study the role of miRNAs in HCC through integration of gene
and miRNA expression profiles combined with target predictions. Traditionally,
miRNAs are investigated individually or in their clusters or families, together
with one or several of their direct targets. Here, I sought to integrate all
information available, that is whole genome mRNA and miRNA expression
profiles of tumors and adjacent non-tumorous tissues of HCC patients with
miRNA target predictions. Through this approach, I gained a more holistic
understanding of the impact of miRNA dys-regulation on HCC formation and
progression. Also, potential collaborative miRNA behavior was investigated,
which might influence the design of therapeutic applications involving miRNAs.
2. To investigate the biological function of miRNAs that exhibit a potentially
relevant role in HCC. To this end, I identified likely miRNAs targets and subse-
quently assessed their involvement in the pathogenesis of the disease, using
pathway enrichment analysis. I summarized biological pathways into categories
to obtain a high level understanding of the biological functions modulated
by these targets. Finally, I established gene networks of significantly differen-
tially expressed targets in each pathway category to investigate key molecules
in these pathways, which are directly or indirectly targeted by differentially
expressed relevant miRNAs.
3. To assess the clinical relevance of dys-regulated, relevant miRNAs and their
differentially expressed targets in HCC. For that purpose, I correlated miRNA
expression with outcome and various other clinical and demographic features.
Similarly, I investigated the association between differentially expressed likely
miRNA targets and clinical features.
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1.6 Significance of this thesis
In this thesis, I employed a systematic approach to investigate the role of miRNAs
in HCC. I identified six potentially relevant miRNAs. MiR-21, miR-93, and miR-221
were up-regulated, which was significantly associated with down-regulation of their
targets; miR-26a, miR-122, and miR-130a were down-regulated in HCC, which was
significantly associated with up-regulation of their targets. Moreover, each of these
miRNAs regulates a largely distinct set of target genes.
Interestingly, all six miRNAs control genes that are involved in critical biological
pathways, that are frequently dys-regulated in cancer. These pathways are related to
the cell cycle, immune system response, or metabolism. The results further suggest
that several miRNAs collaboratively modulate the same biological pathways. Since
the sets of target genes are largely distinct, it is likely that miRNAs regulate these
pathways on different levels, possibly resulting in a more robust and comprehensive
regulatory effect and a certain amount of redundancy in the system. This is an impor-
tant aspect to be considered when miRNAs are employed as therapeutic treatment
option.
Investigation of differentially expressed miRNA targets revealed several down-
stream key genes involved in networks related to the pathways previously identified.
These are IL6, CXCL8, TP53, TP73, and PTEN, which are frequently associated with
cancer. Furthermore, several miRNAs and their targets were correlated with clinical
features, such as hepatitis infection, stage, histological grade, or tumor encapsulation.
Traditionally, miRNAs are investigated individually, in clusters, or in families,
along with one or several of their targets. This thesis presents a significant advance-
ment in our understanding of the role of miRNAs in the pathogenesis of HCC over
these previous studies. Differential expression of miR-21, miR-26a, miR-93, miR-122,
miR-130a, andmiR-221 is associated with the dys-regulation of several critical biolog-
ical pathways in HCC. Several of these miRNAs collaboratively modulate pathways
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related to metabolism, immune system response, or cell cycle. In addition, each
miRNA regulates a largely district set of target genes. Together, these data suggests a
more robust regulatory effect through system redundancy. This should be considered




2.1 HCC patient sample cohort
Tumorous (tumor) and adjacent non-tumorous (normal) tissue samples of 100 HCC
patients were obtained from the National Cancer Centre Singapore (NCCS) Tissue
Repository. Samples were collected from patients with prior written informed consent.
Also, the study was approved by the NCCS Institutional Review Board (approval
NCC_IRB_No_2007/437/B). Demographics and clinical characteristics of patients
are summarized in table 2.1.
2.2 Sample preparation and expression profiling
Contributions: Sample preparation was done by a former student in the laboratory;
samples were sent to Miltenyi Biotec for gene and miRNA expression profiling.
2.2.1 Sample preparation
Total RNA isolation for tumors and normals was performed using the standard RNA
extraction protocols (Trizol). Total RNA integrity was assessed by the Agilent 2100
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Table 2.1: Clinical and demographic characteristics of the patient cohort studied.









































Bioanalyzer platform (Agilent Technologies) and only samples with RNA integrity
number (RIN) greater than six were profiled for gene and miRNA expression [351].
2.2.2 Gene expression profiling
For gene expression profiling, 1µg of each total RNA sample was used as starting
material. Total RNA samples were amplified and labeled using the Agilent Low RNA
Input Linear Amp Kit (Agilent Technologies) following the manufacturers protocol.
cRNA yields and dye-incorporation rates were measured with the ND-1000 Spec-
trophotometer (NanoDrop Technologies). Normals were labeled with Cy3; tumors
were labeled with Cy5. Hybridization was performed according to Agilent’s 60-mer
oligo microarray processing protocol using the Agilent Gene Expression Hybridization
Kit (Agilent Technologies). Briefly, 825ng of the corresponding Cy3- and Cy5-labeled
fragmented cRNA were combined and hybridized overnight (17 hours, 65°C) to
Agilent Whole Human Genome Oligo Microarrays 4x44K (G4112F). Microarrays
were washed with 6x SSPE buffer containing 0.005% N-lauroylsarcosine for 1min
at room temperature followed by a second wash with pre-heated 0.06x SSPE buffer
(37°C) containing 0.005% N-lauroylsarcosine for 1min. The second washing step
was performed with acetonitrile for 30 seconds. Finally, fluorescence signals were
detected using Agilent’s DNA microarray scanner (Agilent Technologies).
2.2.3 MicroRNA expression profiling
For miRNA profiling, samples were labeled according to the undisclosed miRXplore
user manual. Fluorescent-labeled samples were hybridized to miRXplore microarrays
using the a-Hyb hybridization station. Normals were labeled with Hy3; tumors were
labeled with Hy5. Finally, fluorescence intensity signals were detected using an
Agilent laser scanner (Agilent Technologies).
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2.3 Expression profiles publicly available on GEO
Gene and miRNA expression profiles of 100 HCC patient tissue samples were up-
loaded to Gene Expression Omnibus (GEO) and will be publicly available as soon
as these results are published. GEO is a public functional genomics data repository
that accepts array- and sequence-based data. Gene and miRNA expression profiles
were uploaded to GEO through FTP. Raw and pre-processed data are freely available
through the following GEO accession numbers:
GSE62043 Gene expression profiles of 100 patient tissue samples
GSE62007 MiRNA expression profiles of 100 patient tissue samples
GSE62044 SuperSeries providing access to gene and miRNA expression profiles
2.4 R language for statistical analyses
The R statistical program (version 2.15) and several analysis-specific Bioconductor
packages were used to perform statistical analyses. R was employed for the sta-
tistical analysis of gene and miRNA expression profiles. Also, data obtained from
other sources were analyzed with R whenever possible. A comprehensive list of
R packages used is provided in appendix. These package are available through
the Comprehensive R Archive Network (CRAN) or the Bioconductor repository
(http://www.bioconductor.org). A complete list of R packages used is given in
the appendix.
Occasionally, Bash scripts were preferred over R for certain steps in the analysis.
For example, Bash was employed to repeatedly invoke command-line programs with
different input parameters. Gene Set Enrichment Analysis (GSEA) and the MiRanda




2.5.1 Gene expression profiles
First, raw data of gene expression profiles were loaded into a R session through the
R/Bioconductor linear models for microarray data (limma) package (version 3.14.4)
[352]. More specifically, median probe intensities (tumor: rMedianSignal, normal:
gMedianSignal) and median background intensities (tumor: rBGMedianSignal, nor-
mal: gBGMedianSignal) were loaded, as calculated by Agilent’s Feature Extraction
software (version 10.2.1.3). For that purpose, the limma Agilent raw data parse
was used (source=agilent). Next, probes were annotated with RefSeq IDs and
official gene symbols, by mapping Agilent IDs using the hgug4112a.db package [353]
(version 2.8.0).
To reduce non-biological, systematic errors, arrays were subjected to background
correction (normexp) [354], followed by within and between array normalization
[355]. Through background correction, the median background signal intensity is
subtracted from the median probe intensity signal. Next, arrays were corrected for
dye-effects. As two-color arrays were used, profiling each tumor and matched normal
sample on the same array, within-array normalization was employed to correct for
intensity-dependent variations between the two dyes. This was achieved through
Loess within-array normalization, which removes local variations through locally
weighted least-square regression. Finally, between-array normalization, specifically
quantile normalization, was applied to make arrays comparable. Quantile normaliza-
tion imposes essentially identical intensity distributions on each array. Normalized
intensity levels were log2 transformed. Control probes and genes without an official
gene symbol were not considered for further analysis. Also, biological replicates
were removed and replaced by their average intensity signal. For that purpose, the
limma avereps function was employed.
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As a quality control, signal intensity distributions for each array were plotted
before and after gene expression microarray preprocessing and assessed visually. The
similarity of the distributions of intensities was compared.
2.5.2 MicroRNA expression profiles
Similar to gene expression profiles, miRNA expression profiles were loaded into a R
session through the R/Bioconductor limma package. Again, the appropriate parser
was used to load the raw data into a R session (source=imagene) was used. Probes
were annotated through the annotation file provided by Miltenyi Biotec. Background
correction and within- and between-array normalization was performed in the same
way as for gene expression profiles. After normalization, signal intensities were log2
transformed. Replicate probes were replaced by their average through avereps. All
control probes and probes profiling for non-human miRNAs were removed from the
data set.
2.5.3 Batch effect correction
Because samples were profiled in three batches, gene and miRNA expression profiles
were assessed and corrected for possible batch effects. Tumor and normal tissues
were profiled for gene and miRNA expression in 3 batches of 36, 46, and 18 samples
respectively. Processing samples in batches is a source of potential non-biological
bias, such as instrument-to-instrument variation, microarray batch variation, or
variation in sample preparation. Potential batch effects were identified through
visual assessment of principal components calculated through principal component
analysis (PCA). The first two principal components were plotted and samples in
each batch labeled with a different color. This was done for tumor and normal
gene expression profiles individually. The same procedure was employed for miRNA
expression profiles. Batch effects were removed through the ComBat software [356].
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2.6 Analysis workflow to study the role of miRNAs in
HCC
Figure 2.1 illustrates the analysis workflow employed to study the role of miRNAs
and their targets in HCC.
Identify differentially expressed
miRNAs between tumor and nor-
mal tissues of 100 HCC patients
Integrate miRNA and mRNA
expression to select poten-
tially relevant miRNAs in HCC
Identify pathways enriched
in likely gene targets of
relevant miRNAs in HCC
Investigate important dif-
ferentially expressed key
genes of enriched pathways
Associate miRNAs and
their targets with clinico-
pathological characteristics
Figure 2.1: Workflow employed to study the role of miRNAs in HCC through inte-
gration of gene and miRNA expression profiles with target predictions.
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2.7 Differential expression analysis of microRNAs
Differential expression analysis was performed using the standard limma pipeline,
by comparing the normalized log2-transformed intensity levels between tumors and
normals across 100 patient samples. For that purpose, the limma guidelines for a
direct two-color experimental design were followed as described in the limma user
guide. Limma first fits a linear model to the log2 intensity ratios of tumors and
normals. Next, it uses moderated t-statistics to assess the difference in expression
between the two conditions. The appropriate limma functions that implement these
steps were employed for differential expression analysis. To account for multiple
testing, false discovery rates (FDRs) were derived from significance p-values1. A
fold change (FC) greater than 1.5 or smaller than 0.66 (= 11.5) and a FDR less than
0.05 were set as thresholds for statistical significance. The rather low FC cutoff was
set because miRNAs expression changes tend to be subtle. Several miRNA profiling
studies showed that subtle changes in miRNA expression can induce substantial
changes in the biology of a cell [57, 358–360]. Moreover, false positives would be
filtered through the down-stream analysis. For consistency, the same cutoff on fold
change and FDR was used for differential expression analysis of gene expression
profiles.
2.8 Estimation of relative RNA abundance
The relative RNA abundance was estimated to identify which miRNAs are expressed
at high levels and to compare the expression levels between miRNAs in the tumors.
Therefore, a miRNA with the lowest coefficient of variation was identified and used as
a common reference. The relative RNA abundance in the tumors for all differentially
expressed miRNAs was then estimated, using the common reference as a baseline.
1Throughout this thesis, FDR q-values were derived from significance p-values using the Benjamini-
Hochberg method [357] to account for multiple hypothesis testing.
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Therefore, the mean ratio between the miRNA expression in the tumors and the
common reference was calculated and used as relative abundance estimate.
2.9 Identification of relevant microRNAs in HCC
Gene and miRNA expression profiles of tumors and normals were integrated with
target predictions, to identify potentially relevant miRNAs. Firstly, for each differen-
tially expressed miRNA, genes were ranked by the strength of the target regulation,
a measure based on the gene and miRNA expression data in tumors and normals.
Different metrics were tested in order to identify the most appropriate method. Next,
miRNAs with enrichment of predicted targets in highly ranking genes were iden-
tified. In order to reduce the number of false positives, gene sets as predicted by
two different target prediction programs were considered. These are MiRanda and
MirTarget2 target prediction programs. Only differentially expressed miRNAs with
significant enrichment against both sets of predicted targets were considered for
further analysis. These miRNAs were termed “relevant” miRNAs in HCC.
2.9.1 Gene ranking to identify relevant microRNAs in HCC
For each miRNA, genes were ranked according to the strength of regulation based on
the observed expression data. Here, the miRNA-gene interaction was approximated
through a simple model. That is, an increase in miRNA expression would lead to a
decrease in its target gene expression. Therefore, the negative correlation between
the expression of miRNA and the expression of a gene was used as a metic for
miRNA-target-regulation. The higher the negative correlation in expression between
a miRNA and a gene, the stronger the regulatory effect.
Two different ways to calculate the correlation coefficient were explored:
1. The correlation across tumors
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2. The correlation across tumors and normals
For each differentially expressed miRNA, Spearman’s correlation coefficient was
calculated between the miRNA and all probes profiled on the gene expression array.
Here, Spearman’s correlation coefficient was used due to its robustness against
outliers. If multiple probes with the same RefSeq ID were available, only the probe
with the highest absolute correlation coefficient was retained. Genes were ordered
by the negative correlation coefficient. For each miRNA, a file was saved containing
a list of ranked genes and their corresponding negative correlation coefficient. This
was done for both approaches separately.
2.9.2 Target prediction
Target predictions were obtained and prepared for analysis. Targets as predicted by
the MiRanda program (version August 2010) [361] and the MirTarget2 program
(version 4.0) [362] were downloaded through the respective websites.
These programs were chosen for several reasons. Both databases are updated
within a reasonable timeframe and had been updated within the past two years at
the time of analysis. The entire collection of target predictions were available as flat
file, which made it easy to extract gene sets for each miRNA studied. RefSeq IDs
were used for target predictions, critical for mapping between expression profiles
and target prediction. Sets of predicted targets by these two programs further differ
substantially in the number of targets predicted. MiRanda predicts a much larger
set of putative targets for each miRNA than MirTarget2. Also, the sets of predicted
targets are reasonably different for each miRNA. Finally, it was important for further
analysis that at least one target prediction program could be executed locally, in
order to calculate target prediction scores for all genes, even those unlikely to be
biologically regulated.
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From flat files obtained through the MiRanda (http://www.microrna.org)
and MirTarget2 (http://mirdb.org/) websites, gene sets for each miRNA were
extracted and saved to a miRNA-specific file. RefSeq IDs were used for compatibility
reasons with gene expression profiles.
2.9.3 Identification of relevant microRNAs in HCC
GSEA [363] was employed to identify miRNAs where predicted targets are overrepre-
sented in highly negatively correlated genes, subsequently termed relevant miRNAs
in HCC. More specifically, for each miRNA, a list of genes ranked by their correlation
across samples were compared with the set of predicted targets using the GSEA
pre-ranked function. GSEA was the preferred tool because it is flexible enough to
handle the input, that is it allows comparisons against any gene set. In addition, other
tools such as RmiR [364] use Fisher’s exact test for enrichment analysis. Therefore,
genes are split into groups of regulated and non-regulated targets, depending on
their correlation with the miRNA. However, it is not clear what the right cutoff should
be. On the other hand, GSEA uses the actual correlation coefficient and a cutoff is
derived from the enrichment statistic.
For each differentially expressed miRNA, two files were prepared according to the
GSEA user guide. The rank file (.rnk) contains two columns, the first with the gene
names and the second with the corresponding negative correlation coefficient, used
as a ranking metric. The gene set file (.gmt) contains the set of predicted targets.
The GSEA pre-ranked function was configured accodingly. The required and basic
parameters configuration is listed in table 2.2. For advanced fields, the default value
was used. The set_max parameter was set to 10000 in order to consider all predicted
target gene sets. Typically, MiRanda predicts several thousand target genes for a
specific miRNA. Using a Bash script, the GSEA command-line tool was invoked from
the terminal with the configuration as described.
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Table 2.2: GSEA parameter configuration for required and basic fields.
Parameter Value Meaning
gmx *.gmt Gene set file
nperm 10000 Number of random permutationsfor significance estimation
rnk *.rnk Ranked gene list file
collapse false Replaces gene IDs with genesymbols
chip Seq_Accession.chip The IDs used (RefSeq)
scoring_scheme weighted Enrichment statistic
set_max 10000 Maximum gene set size
set_min 15 Minimum gene set size
out gsea_result GSEA output directory
Principle behind the GSEA pre-ranked function
The GSEA pre-ranked function assesses whether in a given gene set (here a biological
pathway or process), the genes tend to have a significantly higher rank than it would
be expected by chance. For that purpose, GSEA steps through the list of genes ordered
by rank and calculates a running sum (enrichment score). If a gene is in the gene set,
the enrichment score is increased by the ranking metric. If a gene is not a predicted
target, the enrichment score is decreased by a standard unit. A standard unit is
defined as the sum of the ranking metrics of all genes in the gene set, divided by the
number of genes not in the gene set. In other words, the running sum is increased by
as much as it is decreased, which assures that the curve always returns to zero in the
end. The enrichment score reported by GSEA is the maximum value attained by the
running sum. The significance of the enrichment is estimated through bootstrapping.
Gene labels in the ordered gene list are scrambled and the enrichment score is re-
calculated. This process is repeated a large number of times to estimate the null
distribution of the enrichment score. A significance p-value can then be estimated
by comparing the number of better enrichment results with the total number of
bootstrapping iterations. By increasing the number of iterations, the precision of a
highly significant p-value can be improved. Also, the normalized enrichment score
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(NES) normalized enrichment score is determined as the test’s enrichment score
divided by the mean enrichment score achieved during bootstrapping. NES allows
comparison of results between tests.
Applying GSEA to identify relevant microRNAs
For each differentially expressed miRNA, GSEA was employed to compare the list
of ranked genes to the set of predicted targets. Enrichment p-values were collected
from the GSEA output for all miRNAs and FDRs were derived using R, to account
for multiple testing. Only miRNAs that satisfied a stringent FDR < 10 3 were
considered statistically significant. Enrichment analysis was carried out with gene
sets as predicted by MiRanda and MirTarget2 individually. MiRNAs with significant
enrichment against at least one target prediction program were tabulated. Only
those that reached significance against both prediction programs, henceforth termed
“relevant miRNAs”, were considered for further analysis.
2.9.4 Sanity checks
Sanity checks were conducted to asses the plausibility of the results based on GSEA
and to exclude possible sources of error or bias.
• For each relevant miRNA, the two sets of all MiRanda and MirTarget2 predicted
targets were compared to exclude the possibility that similar enrichment results
were due to largely overlapping gene sets. The gene sets were visualized
through a Venn diagram. Although a large overlap between the two gene sets
would be expected, there are also a reasonable number of unique genes in each
gene set, due to difference in target prediction.
• Genes were ranked by their negative correlation with the miRNA. Highly
correlated miRNAs might give rise to a highly similar gene ranking and possibly
to similar enrichment results. Therefore, Spearman’s correlation coefficient
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between all relevant miRNAs was calculated. Highly correlated miRNAs (rho >
0.9) would require further investigations.
• Next, the possibility that a randomly ranked gene list would show significant
enrichment against a defined gene set was excluded. For that purpose, sample
labels of a miRNA with significant enrichment against a predicted gene set
were scrambled through random permutations. The negative correlation with
all genes was recalculated and used for ranking the genes. Next, GSEA was
employed to test for enrichment of predicted targets in highly ranking genes.
It was be expected that the gene list generated by scrambling the sample labels
of the miRNA does not show significant enrichment.
• The statistical significance of the enrichment results were assessed through
Fisher’s exact test, a simplification of the GSEA method. Two categorical
variables were derived, one from the expression data, the other from the
target prediction programs. Genes were split into regulated and non-regulated
based on the correlation in expression. An arbitrary cutoff of rho =  0.2 was
used. Furthermore, genes were split into predicted and non-predicted targets,
based on target predictions. Fisher’s exact test was then employed to assess if
regulated genes tend to be predicted targets. Significance was calculated for
both, gene sets predicted by MiRanda and MirTarget2.
2.9.5 Shared likely targets of relevant microRNAs
The number of common likely targets between miRNAs was examined, based on
the results calculated by GSEA. GSEA uses the gene with the maximum enrichment
score estimated by the running sum as a cutoff. The set of predicted targets with a
stronger negative correlation than the gene at the cutoff is called the core enrichment
set. This set of genes was termed “likely targets”, as these are predicted targets
that exhibit a strong negative correlation with the miRNA. For each relevant miRNA,
the set of likely targets was determined from the GSEA output. Gene sets of likely
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targets of up-regulated relevant miRNAs were intersected and visualized using a Venn
diagram. Similarly, gene sets of likely targets of down-regulated relevant miRNAs
were intersected and visualized. Moreover, the subset of differentially expressed
likely targets was identified for each miRNA. Likely targets with a FC > 1.5 or < 0.66
and a FDR < 0.05 were considered significantly differentially expressed. Again, the
shared likely targets for up-regulated relevant miRNAs, down-regulated relevant
miRNAs respectively, were visualized using a Venn diagram.
2.10 Biological function of relevant microRNAs
To better understand the biological relevance of the relevant miRNAs and their likely
targets, the biological function modulated by relevant miRNA was elucidated. Gene
and miRNA expression information and target predictions were integrated into a
single ranking metric. GSEA was then employed to identify significantly enriched
pathways in highly ranking genes. Pathways as defined by Kyoto Encyclopedia of
Genes and Genomes (KEGG) and Gene Ontology (GO) were considered for enrich-
ment analysis.
2.10.1 MiRanda prediction score
For each relevant miRNA, prediction scores with all genes were calculated. Generally,
only good prediction scores are publicly available for download. However, miRNA
target prediction score with all genes were required for integration of expression
information with prediction scores. The MiRanda target prediction program takes
the minimum target prediction score as an input parameter. By setting this input
parameter to a small value, target prediction scores for all genes can be calculated,
even those unlikely to be regulated by a specific miRNA.
The MiRanda target prediction program (version 3.3a) was obtained from the Mi-
Randa website (http://www.microrna.org) [365]. Furthermore, mature miRNA
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sequences were obtained through miRBase (version 19) [37] and 3’-UTR exome se-
quences of all transcripts were downloaded from the UCSC genome browser database
(hg19) [366]. MiRanda was called from a Bash script for each relevant miRNA. The
mature miRNA sequence and 3’-UTR sequences of all transcripts were passed to
MiRanda as input parameters. The minimum target prediction score parameter was
set to 50, a score achieved in at least one location of the 3’-UTR of almost every gene.
Only the location which achieved the highest target prediction score was retained.
For each relevant miRNA, the maximum prediction score with each gene was saved
to a text file.
2.10.2 Gene ranking for biological function annotation
For biological function annotation, genes were ranked by integrating gene and miRNA
expression data with target prediction scores. Specifically, the product between the
negative correlation coefficient across tumors and normals and the MiRanda target
prediction score was calculated and used as a rankingmetric. The negative correlation
coefficient is a measure of the strength of miRNA regulation and the target prediction
score is a measure of the likelihood of miRNA regulation. For each relevant miRNA,
prediction scores were normalized to zero, through subtraction of the lowest score
achieved by any gene. Next, the product between the negative correlation coefficient
and the normalized prediction score was calculated for all genes. Finally, for each
relevant miRNA, a list of genes ranked by the metric described was saved and used
for pathway enrichment analysis.
2.10.3 Biological function annotation using GSEA
The pathways modulated by relevant miRNAs through their likely targets were elu-
cidated using GSEA and pathways as defined by KEGG and GO. For each relevant
miRNA, a rank file (.rnk) was prepared using the previously calculated ranking
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metric (see 2.10.2). Ranked gene lists were compared against gene sets as defined
in Molecular Signatures Database (MSigDB) [367]. KEGG gene sets [368], except
human diseases, and GO gene sets were considered for that purpose. The GSEA con-
figuration was essentially the same as listed in table 2.2, except for “scoring_scheme”.
Here, the “classic” scoring scheme was used instead of “weighted”, in order to avoid
overweighting genes with an extreme value (i.e. gene which are highly correlated
with a high prediction score). The “classic” scoring scheme weights each gene in
the gene set equally rather then using their actual value, in this case the product
between the negative correlation coefficient and the target prediction score.
Ranked genes were compared against KEGG and GO defined gene sets separately.
From the GSEA results, significantly enriched shared pathways and their FDR signifi-
cance levels were extracted and summarized. For subsequent analyses, only KEGG
pathways were considered as KEGG is organized in a more interpretable hierarchical
structure compared to GO.
2.10.4 Summarizing KEGG biological function
In order to gain a better understanding of the biological themes modulated by
individual miRNAs, KEGG pathways were summarized into pathway groups and
functional categories. KEGG gene sets are organized in a conceptual hierarchy,
a tree-like structure comprised of four levels: 1. Root; 2. Functional categories
(e.g. “Cellular processes”); 3. Pathway groups (e.g. “Cell growth and death”); and
4. KEGG pathways or processes (e.g. “Cell cycle”). This structure is implemented
in the R/Bioconductor keggorthology package (version 2.14.0). The package was
employed to summarize the KEGG biological themes of likely miRNA targets into
functional categories and pathway groups.
Significantly enriched KEGG pathways were annotated with their corresponding
pathway group and functional category. The number of pathways under each pathway
group and their FDR range was determined. The data was tabulated and ordered.
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Firstly, functional categories were ordered by the pathway group with the maximum
number of pathways across up-regulated relevant miRNAs. Within each functional
category, pathway groups were ordered by the total number of pathways across
miRNAs. For ties, pathway groups with pathways enriched in all relevant miRNAs
were considered first. Next, pathway groups were ordered by the most significant
minimal FDR across miRNAs. The pathways under the pathway group “Metabolism of
other amino acids” were combined with “Amino acid metabolism” for simplification.
2.10.5 Functional gene network construction from differentially
expressed likely targets
Contributions: Gene network figures were created by Dr Mah Waychamp, a Postdoc in
the laboratory.
Gene networks were established from differentially expressed genes for all relevant
miRNAs in each functional category using Ingenuity Pathway Analysis (IPA) (http:
//www.ingenuity.com). For that purpose, differentially expressed genes in the
core enrichment set of every pathway under each relevant functional category were
consolidated. The gene lists were then uploaded to the IPA software and a network
was inferred through IPA’s network generation algorithm. Briefly, networks are grown,
first considering highly connected neighbors of themost highly connected user defined
gene. The connections are drawn from IPA’s knowledge base. Disconnected smaller
networks are merged by adding linker genes. Direct and indirected connections were
considered in the network generation. The generated network contains about 30
molecules.
In each generated network, links between pathways and genes were drawn using
the IPA knowledge base. Moreover, miRNA target genes were manually annotated
with their respective regulating miRNA(s).
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2.11 Association with outcome and other clinical pa-
rameters
To assess the clinical relevance of relevant miRNAs and their differentially expressed
targets, the expression in tumors and normals was associated with outcome and
other clinical or demographic parameters. Clinical and demographic information
was obtained through the NCCS tissue bank, together with tissue samples. Associa-
tion of relevant miRNAs and their differentially expressed targets with clinical and
demographic parameters was assessed.
The Cox proportional hazards model was employed to test association between
gene or miRNA expression and outcome. Outcome information was available for
the majority of patients (77 out of 100). Only these patients were considered for
clinical association analysis. Associations with other parameters were tested using
the Kruskal-Wallis rank sum test. This test assesses differences in the expression
distribution between different subgroups. Clinical variables listed in table 2.3 were
considered for association analysis. Continuous variables, such as tumor size or AFP
levels, were converted to categorical variables by applying a cutoff.
2.11.1 Association with outcome
Expression of relevant miRNAs and their differentially expressed likely targets was
associated with overall survival (OS) and disease-free survival (DFS), in order to
establish if any of these miRNAs had a direct effect on patient outcome. The Cox
proportional hazards model was employed for survival analysis. For OS, an event was
defined as the disease-related death of a patient. For DFS, an event was defined as
either a tumor relapse or the disease-related death of a patient. The information on
relapse and survival time was combined, considering a relapse event prior to a death
event. Patients who died from a cause unrelated to HCC were excluded from the
analysis. Association with survival was assessed for each relevant miRNA and each
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differentially expressed likely target individually. The expression in tumors and nor-
mals was considered separately. To account for multiple testing, FDRs were derived
from significance p-values. A FDR < 0.2 was considered statistically significant.
For visualisation of a significant association between survival and expression,
patients were split into a group with high expression and a group with low expression
of a particular miRNA or gene. Next, survival probabilities in each subgroup were
illustrated using a Kaplan-Meier plot.
2.11.2 Association with other clinical parameters
The expression in tumors and normals of relevant miRNAs and their likely targets was
associated with categorical variables listed in table 2.3. The Kruskal-Wallis rank sum
test was employed to assess whether a significant difference in expression between
any two categories was observed. The Kruskal-Wallis test was chosen over ANOVA
because the Kruskal-Wallis test is a non-parametric test and does therefore not assume
a normal distribution of the observed variable (expression values). In general, log-
transformed expression intensities follow a normal distribution. However, samples
for which clinical information was not available were excluded, potentially leading
to a set of intensities which are not normally distributed. Association analysis was
performed for each relevant miRNA and each differentially expressed likely target
separately. Furthermore, the expression in tumors and normals was considered
individually. FDRs were derived from test p-values and a FDR < 0.2 was considered
statistically significant.
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Table 2.3: Demographic and clinical variables assessed for their association with
relevant miRNAs and their differentially expressed targets.
Parameter Category 1 Category 2 Category 3
Age  60 > 60 -
Gender Male Female -
Hepatitis infection HBV HCV none
Liver cirrhosis Yes No -
Tumor stage Low (1, 2) High (3A, 3B, 4) -
Histological grade Low (1, 2) High (3, 4) -
Tumor size  5cm > 5cm -
Relapse Yes No -
Encapsulation Complete Incomplete -





Gene and miRNA expression profiles were preprocessed to correct for technical bias. I
applied background correction, followed by within- and between-array normalization.
Quantile normalization, applied to normalize between arrays, makes the distributions
essentially the same across arrays and channels.






























Figure 3.1: Array densities of tumor and normal gene expression profiles before
(normal scale) and after normalization (log2 scale). Tumors were profiled with the
red channel, normals with the green channel.
49
3.1.1 Gene expression profiles
Figure 3.1 illustrates the gene expression profile density distributions before and after
pre-processing. The tumor expression distributions are colored in red, the normals
in green. Before normalization, the intensity levels tend to be higher in tumors
compared to normals. This is corrected for through quantile normalization. After
normalization (figure 3.1b), the density distributions of the expression intensities
are essentially the same for both, tumors and normal.
Batch effects in gene expression profiles
The cohort of 100 tumors and normals was profiles in three batches of 36, 46, and
18 samples. I visually examined the expression profiles of tumors and normals for
potential batch effects using PCA. Figure 3.2 shows the first two principal components
for the tumor channel and the normal channel. Samples in each batch are labeled in
red, blue, and green accordingly. No batch effects were observed between the three
















































































































































































































Figure 3.2: First two principal components of tumor and normal gene expression
profiles. Group 1 is colored in red (36 samples), group 2 in blue (46 samples), and
group 3 in green (18 samples). There were no batch effects between the three groups.
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3.1.2 MicroRNA expression profiles
Similar to gene expression arrays, I pre-processed miRNA expression profiles by
applying background correction, followed by within- and betwee-array normalization.
Figure 3.3 illustrates the density distribution before and after pre-processing. The
density distributions are almost identical after normalization.




































Figure 3.3: Array densities of tumor and normal miRNA expression profiles before
(normal scale) and after normalization (log2 scale). Tumors were profiled with the
red channel, normals with the green channel.
Batch effects in microRNA expression profiles
I visually assessed miRNA expression profiles for batch effects, potentially caused by
profiling the cohort in three groups. For that purpose, I plotted the first two principal
components after normalization (figure 3.4 (a) and (b)). Interestingly, the figures
clearly show a batch effect between the first group (in red) and third group (in green)
of samples profiles. The second group (in blue) is split between the first and the
third group. To remove these batch effect, I employed the ComBat program. After
correction, I used PCA again to confirm that batch effects were properly removed.
























































































































































































































































































































































































































(d) Normals after batch correction
Figure 3.4: First two principal components of tumor and normal miRNA expression
profiles before and after batch correction. (a) and (b): Obviously, miRNA expression
profiles of tumors and normals exhibit a batch effect with two distinct groups. (c)
and (d): The batch effect was successfully removed through the ComBat program.
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3.2 Differentially expressed microRNAs in HCC
To identify miRNAs which potentially play a role in HCC, I first determined differ-
entially expressed miRNAs between tumors and normals across 100 HCC patient
samples. MiRNAs that exhibited an absolute FC greater than 1.5 or smaller than 0.66
and a FDR of less than 0.05 were considered significantly differentially expressed. I
chose this fairly low FC cutoff because small miRNA expression changes potentially
induce substantial alterations of the biology of a cell. Moreover, the down-stream
analysis would filter possible false positives.
A total number of 829 mature human miRNAs were profiled for their expression
using microarrays. Out of these, I found 32 to be significantly differentially expressed
between tumors and normals. Six miRNAs were significantly up-regulated and 26
were significantly down-regulated (figures 3.5 and A.3). Fold change and FDR values



















































































































































Figure 3.5: MiRNAs differentially expressed between tumors and normals. The fold
change between tumors and normals (y-axis) is shown in log2-scale and miRNAs are
sorted by their median fold change. Boxes of down-regulated miRNAs are colored in
green, boxes of up-regulated miRNAs are colored in red.
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From figure 3.5, it is apparent that the variation of ratios varies highly between
differentially expressed miRNAs. Moreover, the variation does not depend on the
magnitude of the fold difference. This is illustrated in figure 3.6, which shows the
variation in the ratios across samples of two miRNAs with a similar fold change.
MiR-195 exhibits less variation compared to miR-302a across samples.
I found that the variation correlates with the miRNA abundance. MiRNAs ex-
pressed at higher levels exhibit a stronger variation across samples and therefore a
stronger variation in the ratio between tumors and normals. To estimate the relative
abundance of differentially expressed miRNAs, I compared the expression in tumors
to a common reference. MiR-651 exhibits a low coefficient of variation in tumors
and is therefore an ideal candidate for a common reference. I estimated the relative
abundance in tumors of differentially expressed miRNAs againstmiR-651. The results
are listed in table 3.1, in the last column. In the example in figure 3.6, the higher













































































































































































































Figure 3.6: Variance of miR-302b and miR-195-5p across samples (log2 ratios).
MiR-195 exhibits more variation across samples due to a higher RNA abundance
(⇠ 2 fold difference).
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Table 3.1: Significantly differentially expressed miRNAs between tumors and nor-
mals. MiRNAs are ordered by FDR. Out of 32 miRNAs, 26 were significantly down-
regulated and six were significantly up-regulated. The relative RNA abundance was






miR-1236 0.65 1.29⇥10 51 1.19
miR-302b-5p 0.63 4.01⇥10 48 0.99
miR-374b-3p 0.66 6.15⇥10 45 0.92
miR-33a-5p 0.65 6.15⇥10 45 1.00
miR-302a-5p 0.65 9.68⇥10 45 0.99
miR-922 0.66 8.91⇥10 43 0.91
miR-186-3p 0.65 1.13⇥10 40 0.87
miR-30a-3p 0.66 1.13⇥10 38 1.27
miR-1224-3p 0.62 1.99⇥10 32 1.42
miR-199a-5p 0.22 2.07⇥10 24 2.50
miR-486-5p 0.56 1.27⇥10 21 1.45
miR-223-3p 0.52 2.76⇥10 18 1.91
miR-199a-3p 0.36 7.22⇥10 18 1.73
miR-21-5p 2.29 1.33⇥10 17 16.19
miR-296-5p 0.62 1.68⇥10 17 1.54
miR-125b-5p 0.47 5.08⇥10 17 7.31
miR-99a-5p 0.53 1.90⇥10 16 3.09
miR-93-5p 1.53 2.16⇥10 16 2.99
miR-145-5p 0.42 2.32⇥10 14 7.47
miR-1274a 1.59 9.26⇥10 14 18.57
miR-130a-3p 0.64 1.14⇥10 12 2.59
miR-125a-5p 0.60 1.83⇥10 11 2.08
miR-195-5p 0.62 8.41⇥10 11 2.10
miR-221-3p 1.55 2.55⇥10 10 2.87
miR-378a-3p 0.66 2.77⇥10 10 3.19
miR-26a-5p 0.63 7.71⇥10 10 15.34
miR-143-3p 0.53 1.81⇥10 09 5.12
miR-150-5p 0.66 2.42⇥10 09 2.38
miR-1469 1.80 6.11⇥10 09 4.85
miR-451a 0.46 1.20⇥10 08 5.28
miR-663a 1.64 9.85⇥10 06 10.00
miR-122-5p 0.60 1.50⇥10 05 145.87
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3.3 Relevant microRNAs in HCC
I identified relevant miRNAs in HCC through integration of gene and miRNA expres-
sion profiles with target predictions. A known weakness of miRNA target prediction
programs is that they generally over-estimate the number of targets regulated by a
specific miRNA. Through integration of target predictions with observed changes in
miRNA and mRNA expression, I identified miRNAs that regulate a significant number
of predicted targets and, at the same time, I eliminated predicted targets that are not
miRNA-regulated in HCC.
I used GSEA to compare the set of predicted targets with genes ranked by their
negative correlation in expression with the miRNA. Gene sets as predicted byMiRanda
and MirTarget2 were considered. I used the negative correlation as a measure
of target regulation and explored two different ways to calculate the correlation:
1) Across tumors; 2) Across tumors and normals.
3.3.1 Ranking genes by correlation across tumors
For each differentially expressed miRNA, I ranked all profiled genes by their negative
correlation with the miRNA across tumors. I then employed GSEA to compare the list
of ranked genes against a set of predicted targets by MiRanda and a set of predicted
targets by MirTarget2. A FDR < 0.05 was considered statistically significant.
The results of the enrichment analysis are summarized in table 3.2. MiR-33a,
miR-93, miR-130a, miR-195, miR-221, miR-26a, and miR-122 showed significant en-
richment against gene sets as predicted by MiRanda and MirTarget2 target prediction
programs. MiR-33a, miR-199a, and miR-150, on the other hand, were only enriched
in targets as predicted by MiRanda.
Through GSEA, I further identified a set of likely targets. These are predicted
targets which, at the same time, exhibit a high negative correlation with the miRNA. I
would expect targets of an up-regulated miRNA to be biased towards down-regulation
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Table 3.2: MiRNAs with enrichment of predicted targets in genes ranked by their cor-
relation with the miRNA across tumors. Target predictions as computed by MiRanda
and MirTarget2 were considered individually. Seven out of nine miRNAs showed
significant enrichment against gene sets predicted by both programs (highlighted,
FDR < 0.05).
Tumor vs Normal GSEA MiRanda GSEA MirTarget2
MiRNA
FC FDR NES FDR NES FDR
miR-33a 0.65 6.15⇥10 45 -1.68 2.1⇥10 5 -1.31 3.1⇥10 2
miR-199a 0.22 2.07⇥10 24 -1.34 2.1⇥10 5 -1.09 3.1⇥10 1
miR-93 1.53 2.16⇥10 16 1.29 2.1⇥10 5 1.47 3.6⇥10 5
miR-130a 0.64 1.14⇥10 12 1.85 2.1⇥10 5 1.89 3.6⇥10 5
miR-195 0.62 8.41⇥10 11 1.45 2.1⇥10 5 1.83 3.6⇥10 5
miR-221 1.55 2.55⇥10 10 1.31 2.1⇥10 5 1.42 3.0⇥10 3
miR-26a 0.63 7.71⇥10 10 1.61 2.1⇥10 5 2.02 3.6⇥10 5
miR-150 0.66 2.42⇥10 09 1.33 2.1⇥10 5 1.26 8.8⇥10 2
miR-122 0.60 1.50⇥10 05 1.48 2.1⇥10 5 1.84 3.6⇥10 5
Table 3.3: Ten most likely targets of miR-93: Genes that showed the strongest
negative correlation with the miRNA and were predicted targets by either MiRanda
or MirTarget2.





VLDLR 1.22 1.0⇥10 02 -0.36 Yes Yes
SLC16A7 1.03 3.7⇥10 01 -0.32 Yes No
TACC1 1.06 1.4⇥10 01 -0.31 Yes No
UBE2B 1.16 1.1⇥10 05 -0.30 Yes Yes
SNCAIP 1.07 1.1⇥10 04 -0.28 Yes No
CCND1 0.51 2.1⇥10 14 -0.28 Yes No
POU6F1 0.84 7.5⇥10 12 -0.28 No Yes
TBC1D9 0.65 2.0⇥10 07 -0.27 Yes Yes
SOCS3 0.27 6.4⇥10 21 -0.26 Yes No
TNFAIP3 0.87 3.3⇥10 02 -0.26 Yes No
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in tumors vs. normals and targets of a down-regulated miRNA to be biased towards
up-regulation in tumors vs. normals.
For example, miR-93 is up-regulated in tumors compared to normals. Table
3.3 lists the ten most likely targets of miR-93. From the table it becomes apparent
that five out of the ten most likely targets tend to be up-regulated, although below
statistical significance. Therefore, I conclude that the ranking metric, ranking the
genes by negative correlation across tumors, is not an appropriate model for miRNA-
target-interaction.
3.3.2 Ranking genes by correlation across tumors and normals
I conceived a potentially more appropriate ranking method that indirectly takes into
account the genes’ direction of change. By ranking the genes by correlation across
tumors and normals, up-regulated miRNAs tends to be negatively correlated with a
down-regulated genes and vice versa. Examples are given in figure 3.8. Therefore, for
each differentially expressed miRNA, I ranked the genes by their negative correlation
with the miRNA across tumors and normals. Again, I employed GSEA to identity
miRNAs which exhibit enrichment of predicted targets in highly negatively correlated
genes.
Table 3.4 provides a high-level summary of the GSEA enrichment analysis. Out of
the 32 differentially expressed miRNAs, nine were significantly enriched against at
least one target prediction program. MiR-21, miR-26a, miR-93, miR-122, miR-130a,
and miR-221 showed significant enrichment in gene sets as predicted by both target
prediction programs, MiRanda and MirTarget2. These six miRNAs were considered
for further analysis. Interestingly, of these six miRNAs, the same number were up-
and down-regulated, even though the differentially expressed miRNAs were not
equally distributed.
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Table 3.4: MiRNAs with enrichment of predicted targets in genes ranked by their
correlation with the miRNA. Target predictions as computed by MiRanda and Mir-
Target2 were considered individually. Six out of nine miRNAs showed significant
enrichment against gene sets predicted by both programs.
Tumor vs Normal GSEA MiRanda GSEA MirTarget2
MiRNA
FC FDR NES FDR NES FDR
miR-30a 0.66 1.13⇥10 38 -0.97 7.3⇥10 1 1.40 <6.0⇥10 4
miR-21 2.29 1.33⇥10 17 1.37 <5.0⇥10 4 1.74 <6.0⇥10 4
miR-93 1.53 2.16⇥10 16 1.49 <5.0⇥10 4 1.56 <6.0⇥10 4
miR-130a 0.64 1.14⇥10 12 1.32 <5.0⇥10 4 1.39 8.0⇥10 3
miR-195 0.62 8.41⇥10 11 1.18 5.5⇥10 3 1.13 2.2⇥10 1
miR-221 1.55 2.55⇥10 10 1.68 <5.0⇥10 4 1.93 <6.0⇥10 4
miR-26a 0.63 7.71⇥10 10 1.31 <5.0⇥10 4 1.34 2.8⇥10 3
miR-663a 1.64 9.85⇥10 6 1.64 <5.0⇥10 4 1.01 6.5⇥10 1
miR-122 0.60 1.50⇥10 5 1.28 <5.0⇥10 4 1.93 <6.0⇥10 4
Two examples of GSEA enrichment plots against MiRanda and MirTarget2 are
shown in figure 3.7. MiR-21 was significantly enriched against MiRanda and Mir-
Target2 predicted targets, whereas miR-30a was enriched only against MirTarget2
predicted targets. Clearly, formiR-30a and MiRanda predict targets, the maximum en-
richment score achieved is lower than in the other examples (⇠ 0.15 vs. 0.25  0.35).
Also, the zero crossing in figure 3.7c of the enrichment curve tends to be near the
center, whereas it is in the right half for those configurations that showed significant
enrichment. Conversely, enrichment plots of significantly enriched miRNAs tend
to rise quickly at the beginning, due to the large number of predicted targets, and
slowly regress towards zero after the point where the maximum enrichment score is
reached. Enrichment plots for all miRNAs in table 3.4, significant and non-significant,
are provided in the appendix figures A.5, A.6, and A.7.
Interestingly, six out of nine miRNAs were shared between the results of the two
ranking metrics. These are miR-26a, miR-93, miR-122, miR-130a, miR-195, and
miR-221. In fact, out of the miRNAs significant in both target prediction programs,
only miR-21 was not previously identified. However, as expected, ranking the genes
by correlation across tumors and normals substantially changed the sets of likely
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targets. Table 3.5 lists the updated ten most likely targets of miR-93. All ten likely
targets are down-regulated in tumors compared to normals. In fact, all except one
reached statistical significance (FC < 0.66, FDR < 0.05). These results suggest that
the gene ranking by correlation across tumors and normals is an appropriate model
for identification of relevant miRNAs and their likely targets.
Next, I took a closer look at the expression patterns of the down-regulated likely
targets of miR-93 listed in table 3.5. Therefore, I plotted the expression of miR-
(a) miR-21/MiRanda (b) miR-21/MirTarget2
(c) miR-30a/MiRanda (d) miR-30a/MirTarget2
Figure 3.7: Example GSEA enrichment plots. (a) and (b) MiR-21 was significantly
enriched against both MiRanda and MirTarget2 predicted targets (MiRanda: NES
= 1.37, FDR < 5⇥10 4; MirTarget2: NES = 1.74, FDR < 6⇥10 4). (c) and (d) MiR-
30a was significantly enriched only against MirTarget2 predicted targets (MiRanda:
NES =  0.97, FDR = 0.73; MirTarget2: NES = 1.40, FDR < 6⇥ 10 4).
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Table 3.5: Ten most likely targets of miR-93: Genes that showed the strongest
negative correlation with the miRNA and were predicted targets by either MiRanda
or MirTarget2. The correlation was derived from the expression across tumors
and normals between the miRNA and the gene. All except one likely targets are
significantly down-regulated in tumors vs. normals.





MAN1C1 0.25 4.1⇥10 29 -0.51 Yes No
ANGPTL1 0.31 7.4⇥10 25 -0.50 Yes No
PLSCR4 0.35 1.9⇥10 26 -0.49 Yes No
MYO10 0.33 1.2⇥10 24 -0.48 Yes No
TFPI2 0.22 3.5⇥10 30 -0.48 Yes No
RND3 0.18 7.5⇥10 31 -0.48 Yes Yes
SYNE1 0.43 3.1⇥10 30 -0.48 Yes Yes
LRRC4 0.74 1.8⇥10 26 -0.47 Yes No
COLEC10 0.39 7.7⇥10 34 -0.47 Yes No
LRAT 0.29 1.8⇥10 30 -0.46 Yes No
93 against the expression of each of the ten most likely targets across tumors and
normals (figure 3.8 and appendix figureA.4). As expected, there is a strong negative
correlation between miR-93 and its most likely targets MAN1C1 and ANGPTL1, as
evident from figure 3.8. Furthermore, the figure also illustrates the differential
expression of miR-93 and the genes, between tumors and normals. MiR-93 exhibits a
generally higher expression in tumors compared to normals, whereas the expression
of MAN1C and ANGPTL1 is higher in normals compared to tumors. Interestingly, the
tumors exhibits a higher variance across samples as the dots are more scattered than
the normals, which suggests that a higher heterogeneity among tumor samples. I
found similar patterns while comparing the expression of miR-93 with other likely






























































































































































































































































































































































































































Figure 3.8: Expression of miR-93 (log2 scale) and its two most likely targets in tumors and normals (log2 scale) as determined by GSEA.
Clearly, there is a strong negative correlation between miR-93 and the two targets, MAN1C1 (rho =  0.51) and ANGPTL1 (rho =  0.50).
The figures further illustrate the differential expression of the miRNA as well as the targets. MiR-93 expression is generally higher in the
tumors compared to the normals and vice versa for the genes. Moreover, it is interesting to note that the tumor expression appears to be more


























Figure 3.9: Diagrams showing the overlap between target predictions as calculated by MiRanda and MirTarget2. MiRanda predicts much
larger sets of putative targets than MirTarget2. In general, about half of the targets predicted by MirTarget2 are also predicted by MiRanda.
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3.3.3 Sanity checks
Sets of MiRanda and MirTarget2 predicted targets reasonably different
I compared the gene sets as predicted by MiRanda and MirTarget2 to make sure the
predicted gene sets are reasonably different, excluding the possibility that significant
enrichment in MiRanda and MirTarget2 predicted targets is observed because one
gene set is a subset of the other. Moreover, with enrichment analysis against targets
predicted by two different target prediction algorithms without largely overlapping
gene sets increases the specificity of the result. The overlap between MiRanda and
MirTarget2 gene sets for each relevant miRNA is illustrated in figure 3.9. I found
that generally about half of the MirTarget2 predicted targets are also predicted by
MiRanda. The number of targets predicted by the two programs largely differs.
MiRanda predicts substantially more target genes than MirTarget2.
Between-microRNA correlation
Due to the specific design of the analysis, if any two miRNAs were highly correlated
in expression, they might give rise to similar enrichment results, given a similar set
of predicted targets. Therefore, I assessed whether any two relevant miRNAs were
highly correlated. For that purpose, Spearman’s correlation coefficient was calculated
for each pair of relevant miRNA.
Table 3.6: Pairwise correlation between relevant miRNAs. The upper triangle shows
Spearman’s correlation coefficient and the lower triangle the significance p-value.
No pair of miRNAs is strongly correlated. Two pairs of miRNAs are moderately
correlated. These are miR-26a/miR-130a and miR-93/miR-221.
PPPPPPPp-value
rho
miR-21 miR-26a miR-93 miR-122 miR-130a miR-221
miR-21 -0.21 0.00 -0.29 -0.09 0.26
miR-26a < 10 2 0.00 0.19 0.56 -0.02
miR-93 0.97 0.94 -0.16 -0.19 0.60
miR-122 < 10 2 0.01 0.02 0.04 -0.22
miR-130a 0.19 < 10 2 0.01 0.58 -0.08
miR-221 < 10 2 0.73 < 10 2 < 10 2 0.23
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Table 3.6 summarizes the pairwise correlation coefficients and significance levels
between miRNAs. No pair of relevant miRNAs showed a strong correlation in expres-
sion across tumors and normals. Two pairs of miRNAs were moderately correlated.
The correlation between miR-26a and miR-130a was rho = 0.56 and the correlation
between miR-93 and miR-221 was rho = 0.60.
No enrichment with scrambled sample labels
To verify that the significant enrichment observed is due to a real biological observa-
tion and not due to random chance, I scrambled the sample labels of miR-30a and
reapplied enrichment analysis. MiR-30a showed strong enrichment of MirTarget2
predicted targets in negatively correlated genes. I scrambled the sample labels of
miR-30a and recalculated the negative correlation with all genes with their actual
sample labels. Next, I used GSEA to evaluate if genes ranked by their negative
correlation coefficient were still significantly enriched against MirTarget2 predicted
targets.
(a) Actual sample labels (b) Scrambled sample labels
Figure 3.10: MiR-30a with actual and scrambled sample labels. (a) Significant
enrichment of MirTarget2 predicted targets in highly negatively correlated genes
(p-value < 10 3). (b) With scrambled sample labels, predicted targets are no longer
enriched in highly negatively correlated genes (p-value = 0.85).
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The enrichment plots for both, the actual gene ranking and the gene ranking
calculated from scrambled miRNA sample lables are shown in figure 3.10. I found
that MirTarget2 predicted targets were no longer significantly enriched in highly
negatively correlated genes (p-value = 0.13). This result suggests that statistical
significance is due to a real biological effect and not merely due to a specific data
constellation.
Confirmation of GSEA results through Fisher’s exact test
I applied Fisher’s exact test as a simplified approach for enrichment analysis and
compared the statistical significance with results calculated by GSEA. First, I split
ranked genes into two groups of miRNA regulated and non-regulated genes. For
that purpose, I used an arbitrary cutoff on correlation (rho =  0.2). Furthermore, I
categorized genes into predicted and non-predicted targets, according to MiRanda
and MirTarget2 predictions. I then applied Fisher’s exact test to examine the associa-
tion between correlation and target prediction. FDRs were derived from significance
p-values to account for multiple testing.
Table 3.7: Confirmation of GSEA results through Fisher’s exact test. The results
strongly agree with GSEA. More specifically, miR-30a, miR-195, andmiR-663a exhibit
the least significant enrichment in either MiRanda or MirTarget2 predicted targets. All
other miRNAs satisfied the condition FDR  0.1 in both target prediction programs.
miRNA
Fisher’s FDR GSEA FDR
MiRanda MirTarget2 MiRanda MirTarget2
miR-30a 1.85⇥10 01 7.71⇥10 06 7.3⇥10 1 <6.0⇥10 4
miR-21 6.42⇥10 06 7.71⇥10 06 <5.0⇥10 4 <6.0⇥10 4
miR-93 2.40⇥10 12 7.71⇥10 06 <5.0⇥10 4 <6.0⇥10 4
miR-130a 3.34⇥10 05 1.15⇥10 02 <5.0⇥10 4 8.0⇥10 3
miR-195 9.99⇥10 02 7.06⇥10 01 5.5⇥10 3 2.2⇥10 1
miR-221 3.71⇥10 09 5.66⇥10 02 <5.0⇥10 4 <6.0⇥10 4
miR-26a 6.34⇥10 03 1.00⇥10 01 <5.0⇥10 4 2.8⇥10 3
miR-663a 1.30⇥10 03 2.75⇥10 01 <5.0⇥10 4 6.5⇥10 1
miR-122 5.20⇥10 02 7.93⇥10 03 <5.0⇥10 4 <6.0⇥10 4
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The results are summarized in table 3.7. These results strictly confirmed the
findings based on GSEA. The miRNAs that showed significant enrichment in targets
as predicted by both programs exclusively exhibit a FDR  0.1. I observed higher
FDRs only for miR-30a, miR-195, and miR-663a in either MiRanda or MirTarget2
predictions, which agreed with results prodced by GSEA. Overall, significance levels
were less strong when assessing enrichment through Fisher’s exact test. I think that
this is due to the fact that Fisher’s exact test does not take into consideration the
strength of the correlation, but reduces it to a categorical variable through a cutoff.
3.3.4 Few likely targets shared between relevant microRNAs
I identified likely targets and a subset thereof, differentially expressed likely targets,
which are shared between relevant miRNAs. A likely targets is a gene that exhibits
a highly negative correlation with the miRNA and in addition, is predicted to be a
target. I considered targets as predicted by the MiRanda target prediction program.
For each relevant miRNA, I determined its list of likely targets. I further identified
those likely targets which, in addition, were significantly differentially expressed
between tumors and normals (FC > 1.5 or FC < 0.66, FDR < 0.05) and termed them
differentially expressed likely targets.
Figure 3.11 shows the differentially expressed likely targets shared between the
three up-regulated relevant miRNAs, the three down-regulated relevant miRNAs
respectively. A similar figure with all likely targets is provided in the appendix (figure
A.8). Interestingly, only few targets are shared between the respective groups of
relevant miRNAs. The low number of shared likely targets suggests that each relevant
miRNA regulates a largely distinct group of genes.
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Shared likely up−regulated targets










Shared likely down−regulated targets










Figure 3.11: Shared differentially expressed likely targets of relevant miRNAs. Few
likely targets are shared between up-regulated relevant miRNAs, down-regulated
relevant miRNAs respectively. Each relevant miRNA targets a mostly distrinct set of
genes.
3.4 Biological function of microRNA targets
To better understand the biological functions modulated by these relevant miRNAs,
I investigated the pathways using pathway enrichment analysis of likely miRNA
targets. For that purpose, I combined the previously derived gene ranking, based
on negative correlation across tumors and normals, with target prediction. I used
the MiRanda program to calculate prediction scores for relevant miRNAs with all
genes. Next, I ranked the genes by the product of the two parameters, a metric for
miRNA target regulation. The negative correlation is a measure for the strength of
miRNA regulation and the prediction score is a measure for the likelihood of miRNA
regulation.
I employed GSEA to identify enriched pathways in highly ranked genes. I investi-
gated gene sets as defined by KEGG and GO. I excluded human disease gene sets
from KEGG and focused the analysis on cellular pathways and processes. For each
relevant miRNA, I performed GSEA enrichment analysis of KEGG and GO pathways
separately.
3.4.1 Extensive overlap between pathways enriched in targets of
down-/up-regulated relevant microRNAs
KEGG pathways
I employed GSEA to identify KEGG pathways that showed significant enrichment in
highly ranked targets of relevant miRNAs. I extracted KEGG pathways modulated
by relevant miRNAs from the GSEA output and identified those which are shared
between the respective groups of relevant miRNAs. Pathways with a FDR < 0.2
were considered significantly enriched. Figure 3.12 summarizes the shared KEGG
pathways within the groups of up-regulated relevant miRNAs and down-regulated
relevant miRNAs.
I was surprised to discover that the majority of pathways are shared between at
least two out of three relevant miRNAs within each group. That is, more than 60%
(13/21) are shared within the group of down-regulated relevant miRNAs and more
than 80% (58/72) are shared within the group of up-regulated relevant miRNAs.
Interestingly, I found more pathways significantly enriched in targets of up-regulated
relevant miRNAs. The actual pathways are listed in appendix tables A.1 and A.2.






















Figure 3.12: Majority of KEGG pathways are shared between down-/up-regulated
relevant miRNAs. Fewer pathways were significantly enriched in targets of down-
regulated miRNAs than in targets of up-regulated miRNAs.
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Gene Ontology pathways






















Figure 3.13: Majority of GO pathways are shared between down-regulated/up-
regulated relevant miRNAs.
Similarly to KEGG, I determined enriched GO pathways in targets of down-
regulated and up-regulated relevant miRNAs. The number of shared pathways
for targets of down-/up-regulated miRNAs are summarized in figure 3.13. Again,
I found a substantial overlap between pathways enriched in targets of the three
down-regulated relevant miRNAs, between pathways enriched in targets of the three
up-regulated relevant miRNAs respectively. Down-regulated relevant miRNAs shared
more than 60% (42/67) of the pathways enriched in their targets. Up-regulated
relevant miRNAs shared more than 50% (58/108) of pathways enriched in their
targets. A complete list of shared pathways between all three respective differentially
expressed miRNAs is provided in the appendix (tables A.3 and A.4). Due to the
large number of pathways, only those which were shared between the three down-
regulated or the three up-regulated relevant miRNAs are listed in the table.
3.4.2 Biological function modulated by relevant microRNAs
From the shared KEGG and GO pathways enriched in targets of up- or down-regulated
relevant miRNAs, I obtained a first glimpse of biological function modulated. KEGG
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and GO pointed towards similar biological themes, as evident from the respective
tables in the appendix (A.1/A.3 and A.2/A.4). Targets of down-regulated relevant
miRNAs are involved in cell cycle processes, specifically replication and repair mech-
anisms. Targets of up-regulated relevant miRNAs, on the other hand, are involved in
metabolism and immune system pathways.
3.4.3 Summarizing KEGG pathways
To better understand the biological themes modulated by individual miRNAs through
their targets, I organized and summarized the KEGG pathways enriched in likely
targets of relevant miRNAs. For that purpose, I used the KEGG conceptual hierarchy
as a basis for organization of the data. This hierarchy can be represented as a
tree of four levels, where the first level is the root node. Below the root node are
several child nodes here called: “functional categories”. Each functional category is
comprised of several “pathway groups”, and each pathway group contains multiple
KEGG pathways. The data is presented in table 3.8. It shows the number of pathways
in each pathway group, together with the corresponding FDR range. I only considered
enriched pathways that showed statistically significant enrichment (FDR < 0.2).
I had previously shown that within the group of up-regulated relevant miRNAs
and within the group of down-regulated relevant miRNAs, a substantial number of
pathways are shared. Interestingly, between the two groups of relevant miRNAs, en-
riched pathways are largely mutually exclusive. For example, within the metabolism
functional category, amino acid, carbohydrate, and lipid metabolism are enriched
in targets of up-regulated relevant miRNAs. Conversely, nucleotide and glycan
biosynthesis are enriched in targets of down-regulated relevant miRNAs. Strikingly,
organismal system pathways were only enriched in targets of up-regulated relevant
miRNAs. On the other hand, pathways related to genetic information processing
were only enriched in targets of down-regulated relevant miRNAs.
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Surprisingly, the only group of pathways which showed enrichment in both
up-regulated and down-regulated relevant miRNAs is cell growth and death. This
pathway group will be discussed in more details below.
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Table 3.8: Summary of biological themes associated with miRNA targets. Functional categories were sorted by the highest ranking pathway
group. For each pathway group, the number of pathways enriched in miRNA targets is listed, with the range of FDRs in brackets. Within
functional category, pathway groups were ordered by the highest total number of underlying pathways in up-regulated miRNAs. For ties,
groups with pathways in all three miRNAs were prioritized followed by lower minimum FDRs.
Number of pathways (FDR range)
Up-regulated miRNAs Down-regulated miRNAs
Functional
category Pathway group
miR-21 miR-93 miR-221 miR-26a miR-122 miR-130a
Metabolism
Amino acid 10 (<0.01) 11 (<0.01–0.11) 11 (<0.01–0.05) – 1 (0.18) –
Carbohydrate 9 (<0.01–0.07) 8 (<0.01–0.08) 9 (<0.01–0.13) – – –
Lipid 7 (<0.01–0.09) 5 (<0.01–0.09) 5 (<0.01–0.11) 1 (0.1) – –
Xenobiotics biodegradation 3 (<0.01) 3 (<0.01) 3 (<0.01) – – –
Cofactors and vitamins 3 (<0.01–0.07) 2 (<0.01–0.03) 2 (<0.01–0.12) – – –
Energy 1 (0.01) 1 (0.05) 1 (0.02) – – –
Glycan biosynthesis – – 1 (0.13) 1 (0.14) 1 (0.13) 1 (0.12)
Nucleotide – – – 2 (0.02–0.11) 1 (0.16) 2 (0.03–0.19)
Organismal
systems
Immune system 8 (<0.01–0.12) 12 (<0.01–0.2) 11 (<0.01–0.17) – – –
Endocrine system 3 (<0.01–0.1) 2 (0.01–0.03) 3 (0.01–0.16) – – –
Circulatory system 1 (0.07) 1 (0.13) 1 (0.17) – – –
Development – 2 (0.09–0.12) 1 (0.02) – – –




Signal transduction 3 (0.04–0.18) 4 (0.08–0.2) 4 (0.06–0.2) – – –
Signal. molecules & interaction 3 (0.05–0.08) 3 (0.02–0.12) 1 (0.1) – – –
Membrane transport – – 1 (0.17) 1 (0.01) 1 (0.1) 1 (0.02)
Cellular
processes
Cell growth and death 2 (<0.01–0.07) 2 (0.04–0.09) 2 (0.01–0.12) 2 (0.02–0.09) 2 (0.17) 2 (0.03–0.1)
Cell communication – 2 (0.08–0.12) 2 (0.11–0.2) – – –




Translation – – – 1 (0.18) 2 (0.08–0.15) –
Folding, sorting and degradation – – – 2 (0.04–0.17) 1 (0.11) 2 (0.12–0.18)
Transcription – – – 2 (0.01–0.06) 1 (0.11) 2 (0.02–0.15)
Replication and repair – – – 5 (<0.01–0.07) 2 (0.07–0.1) 4 (<0.01–0.15)
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3.4.4 Up-regulated relevantmicroRNAsmodulatemetabolism and
immune-system processes
Targets of up-regulated relevant miRNAs are involved in metabolism pathways, specif-
ically in amino acid, carbohydrate, and lipid metabolism (table 3.8). Genes involved
in metabolism are over-represented in targets of up-regulated relevant miRNAs. I
found the largest number of pathways across three up-regulated relevant miRNAs
to be in the group of amino acid metabolism, with 32 pathways. Carbohydrate and
lipid metabolism showed similarly high numbers of enriched pathways in targets of
miR-21, miR-93, and miR-221, with 26 and 17 pathways. Furthermore, I found en-
richment of pathways related to xenobiotics biodegradation, cofactors and vitamins,
and energy metabolism.
The second most important group of pathways enriched in targets of up-regulated
relevant miRNAs are related to the immune system. In total, enrichment analysis
revealed 31 immune system pathways significantly enriched across three up-regulated
relevant miRNAs. I counted fewer enriched pathways related to the endocrine system
(eight), the circulatory system (three), development (three), and the nervous system
(two).
Up-regulated relevant miRNAs are also found significantly involved in the modu-
lation of environmental information processing and cellular processes. The results
showed that targets of miR-21, miR-93, and miR-221 are enriched in the pathway
groups related to signal transduction, signaling molecules and interaction, cell growth
and death, cell communication, and transport and catabolism.
3.4.5 Down-regulated relevant microRNAs modulate replication
and repair
Targets of down-regulated relevant miRNAs are primarily involved in genetic informa-
tion processing, specifically in replication and repair. The largest number and some
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of the most significantly enriched pathways in targets of down-regulated relevant
miRNAs are related to replication and repair. I further found enrichment of pathways
related to transcription, folding, sorting and degradation, and translation.
Targets of down-regulated relevant miRNAs are further involved in pathway
groups related to cell growth and death (six), nucleotide metabolism (five), glycan
biosynthesis (three), and membrane transport (three).
3.4.6 Up- and down-regulated relevantmicroRNAsmodulate cell
growth and death
I already noted that cell growth and death pathways were enriched in targets of
up-regulated and down-regulated relevant miRNAs. Targets of all six relevant miR-
NAs showed enrichment of two pathways related to cell growth and death. Table
3.9 lists the pathways enriched for each relevant miRNA and the significance of
enrichment. Targets of all six relevant miRNAs are significantly involved in p53
signaling. Moreover, I found that targets of up-regulated relevant miRNAs are sig-
nificantly involved in apoptosis. These targets are frequently down-regulated as a
consequence of miRNA regulation. None of the down-regulated relevant miRNAs
showed significant enrichment in apoptosis. However, they modulate cell cycle,
which was significantly enriched in targets of all down-regulated relevant miRNAs.
Table 3.9: Cell growth and death pathways modulated by targets of up-regulated and
down-regulated relevant miRNAs. While up-regulated relevant miRNAs modulate
apoptosis, down-regulated relevant miRNAs modulate cell cycle. In addition, both
groups of relevant miRNAs modulated p53 signaling.
KEGG pathway
GSEA FDR
Up-regulated miRNAs Down-regulated miRNAs
miR-21 miR-93 miR-221 miR-26a miR-122 miR-130a
P53 signaling <0.01 0.04 0.01 0.09 0.17 0.1
Apoptosis 0.07 0.09 0.12 - - -
Cell cycle - - - 0.02 0.17 0.03
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3.4.7 Subtle differences within groups of relevant microRNAs
Even though within each group of relevant miRNAs, targets are involved in essentially
the same cellular processes, I found interesting differences between the pathways
modulated. Pathways enriched in targets of at least one relevant miRNA are listed in
the appendix tables A.1 and A.2
Targets ofmiR-26a andmiR-122 are involved in protein synthesis, which is not the
case for targets of miR-130a. However, miR-130a, together with miR-26a, regulate
genes involved in protein degradation through proteolysis.
Down-regulated relevant miRNAs modulate processes associated with transcrip-
tion. Targets of all three down-regulated relevant miRNAs are involved in splicing. In
addition, miR-130a acts on transcription initiation factors of the basal transcription
machinery. MiR-26a, on the other hand, controls genes related to RNA polymerase,
suggesting a role in RNA synthesis.
Similarly, miR-26a, miR-122, and miR-130a modulate processes associated with
replication and repair. A closer look reveals that targets of all three miRNAs are
involved in DNA replication and homologous recombination. Targets of miR-26a and
miR-130a are further involved in single-strand damage repair mechanisms: MMR,
base excision repair, and nucleotide excision repair (miR-26a only).
All three relevant miRNAs are involved in the modulation of processes related to
immune-system response, such as chemokine signaling. However, several processes
are modulated by a subset of up-regulated relevant miRNAs only. T-cell receptor
signaling and leukocyte transendothelial migration are modulated by miR-93 and
miR-221, but not miR-21. Furthermore, only targets of miR-93 are involved in
NOD-like receptor signaling.
Signal transduction as well as cell communication and interaction are other
pathway groups modulated by up-regulated relevant miRNAs. For example, all three
miRNAs modulate both, TGF  signaling and Jak-STAT signaling. MiR-21 and miR-93
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further modulate VEGF signaling, extracellular matrix (ECM) receptor interaction,
and cytokine-cytokine receptor interaction. MiR-93 and miR-221 modulate MAPK
signaling, Gap junction, and focal adhesion. And targets of miR-221 are also involved
in mTOR signaling.
Although the majority of the processes are shared between up-regulated relevant
miRNAs, down-regulated relevant miRNAs respectively, I found some interesting
differences within each group of miRNAs.
3.4.8 GO pathway enrichment results
I did not consider GO pathways in my subsequent analysis, because of its rather
complex hierarchical structure. Although GO pathways are organized in a hierar-
chical structure, the tree is complex and difficult to summarize appropriately. For
example, a nodes in a pathway tree might not only have several child nodes, but also
several parent nodes. Furthermore, the number of levels in each pathway varies. An
additional complexity arises from the fact that not only leaf nodes can be enriched,
but also their parent nodes. In general, I found that the results of the KEGG and the
GO pathway enrichment analyses were comparable. Therefore, I decided to focus on
KEGG pathways only in the down-stream analysis.
3.5 Gene network identify key genes involved in path-
ways associated with microRNA targets
Contributions: Gene network figures were created by Dr Mah Waychamp, a Postdoc in
the laboratory.
We used the IPA network generation algorithm to visualize interactions within
groups of pathways and identify highly connected genes in these pathways. For
that purpose, we identified significantly differentially expressed miRNA targets of
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interesting pathway groups. We focused our investigation on four functional sub-
groups. Firstly, we considered metabolism pathway groups, because of the large
number of pathways enriched. Specifically, we combined down-regulated targets of
amino acid metabolism, carbohydrate metabolism, and lipid metabolism. We were
also interested in pathway groups related to the immune system, namely immune
system response and inflammation. In addition, we considered cell growth and death
because it is the only pathway group that is modulated by targets of up-regulated
and down-regulated relevant miRNAs. Finally, we were interested in the interactions
between up-regulated targets of down-regulated relevant miRNAs. Specifically, tar-
gets which are involved in genetic information processing, such as replication and
repair, transcription, and the related group of nucleotide metabolism pathways. We
employed the IPA network generation algorithm, which builds a network by adding
genes that exhibit a high connectivity with the user provided gene list. We allowed
for direct and non-direct interactions.
3.5.1 IL6 and CXCL8: key genes in metabolism
The gene interaction network generated from differentially expressed miRNA targets
involved in the amino acid, carbohydrate, and lipid metabolism pathway groups is
shown in figure 3.14. As evident from the figures, the cytokines IL6 and CXCL8 are
highly connected within the network, suggesting they are key genes involved in cell
metabolism. Both genes are significantly down-regulated in tumors compared to
normals and targets of miR-93.
3.5.2 TP53 and CXCL8: key genes in immunity
Figure 3.15 illustrates interactions between immune system response genes. The
initial gene set was based on down-regulated targets of up-regulated relevant miR-
NAs, involved in pathways related to the immune system. Interestingly, the tumors
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suppressor TP53 and cytokine CXCL8 are the most highly connected genes involved
in immune system response pathways. TP53 is not a direct target of miR-21, miR-93,
or miR-221, but was added to the network due to its high connectivity with the
provided target gene list. CXCL8, on the other hand, is down-regulated in tumors
and a target of miR-93. Furthermore, we previously found CXCL8 to be critically
involved in metabolism pathways (figure 3.14).
3.5.3 TP53 and TP73: key genes in cell growth and death
Figure 3.16 shows the network inferred from miRNA targets involved in cell growth
and death pathways. Because these pathways are modulated by all relevant miRNAs,
the networks comprises up- and down-regulated targets. Figure 3.16 illustrates an
interesting result that we highlighted earlier (see table 3.9). Up-regulated targets of
down-regulated relevant miRNAs are involved in cell cycle progression and down-
regulated targets of up-regulated miRNAs are involved in apoptosis. The most
connected genes in the network are TP53 and TP73. This is consistent with the
results of the pathway enrichment analysis, which revealed that all six relevant
miRNAs regulate genes involved in p53 signaling (table 3.9). Both, TP53 and TP73
are not directly modulated by any of the relevant miRNAs and therefore not part of
the original list of differentially expressed target genes.
3.5.4 PTEN: key gene involved in cell proliferation
The network in figure 3.17 is based on a collection of differentially expressed genes
involved in cell proliferation and related pathway groups, such as DNA replication,
DNA metabolism, and transcription. Tumor suppressor PTEN is the most highly
connected gene in the network. Other interesting, highly connected genes include






























Figure 3.14: IL6 and CXCL8 are key genes of the amino acid, carbohydrate, and lipid metabolism interaction network. Significantly down-
regulated targets of up-regulated miRNAs are colored in green. Different shades of green indicate the level of down-regulation. A box above






















Figure 3.15: TP53 and CXCL8 are key genes of the inflammation and immune system response pathways. Different shades of green indicate





















Figure 3.16: TP53 and TP73 are key genes of the cell growth and cell death pathways. Genes colored in green are down-regulated and genes
colored in red are up-regulated. Interestingly, down-regulated targets of up-regulated relevant miRNAs are involved in apoptosis. On the




































Figure 3.17: PTEN is a key gene of the genetic information processing functional category and nucleotide metabolism. PTEN itself is not a
target of miR-26a, miR-122, or miR-130a. However, several of its up- and down-stream interacting genes are controled by down-regulated
relevant miRNAs. Different shades of red indicate the level of over-expression of the miRNA targets.
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3.6 Clinical parameters associated with microRNAs
and their differentially expressed targets
I assessed the clinical significance of six relevant miRNAs through association of
miRNA expression with OS, DFS, and other clinical and demographic parameters.
I excluded 23 samples from the analysis for which survival information was not
available. Expression levels in tumors and normals were assessed individually.
3.6.1 No significant association between expression of relevant
microRNAs and outcome
Table 3.10 summarizes the association between expression levels in tumors and
normals of relevant miRNAs and outcome. None of the relevant miRNAs showed
a significant association between expression in tumors or normals and OS or DFS
(FDR < 0.2). I found the strongest, non-significant association between miR-130a
tumor expression and disease-free survival (FDR = 0.37). Interestingly, although
miR-130a is down-regulated in tumors compared to normals, the hazard ratio (HR)
increases with its expression (HR = 1.62).
Table 3.10: Univariate association between relevant miRNAs and outcome. The Cox
proportional hazards model was employed to associate miRNA tumor and normal
expression with OS and DFS. A HR greater than one indicates that a higher miRNA
expression increases the risk for an event, and vice versa.
miRNA
Tumor Normal
OS DFS OS DFS
HR FDR HR FDR HR FDR HR FDR
miR-21 1.09 0.68 0.88 0.79 1.23 0.97 1.12 0.94
miR-26a 0.74 0.65 0.86 0.84 0.93 0.97 0.82 0.94
miR-93 0.86 0.68 0.95 0.86 1.31 0.97 1.21 0.94
miR-122 1.48 0.65 1.12 0.84 0.91 0.97 0.93 0.94
miR-130a 1.49 0.65 1.62 0.37 1.28 0.97 0.96 0.94
miR-221 0.81 0.66 1.05 0.86 1.03 0.97 0.96 0.94
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3.6.2 Several microRNAs associated with clinical parameters
I further correlated the expression of relevant miRNAs with clinical and demographic
parameters and found several miRNAs associated with age, hepatitis infection, AFP
levels, and histological grade, in either tumors or normals. I employed the Kruskal-
Wallis rank sum test for hypothesis testing and considered a FDR < 0.2 statistically
significant. The FDRs for all tests are listed in table 3.11, with significant associations
highlighted in bold-face.
Each significant association between a relevant miRNA and a clinical or demo-
graphic parameter is illustrated with a box plot in figure 3.18. I found the expression
of miR-122 in tumors to be significantly associated with patients’ AFP levels. High
miR-122 expression correlated with low AFP levels (FDR = 0.20). Furthermore, the
expression of miR-221 in tumors is associated with age as well as hepatitis infection.
Tumors of patients older than 60 exhibit lower miR-221 expression (FDR = 0.13).
Moreover, patients with a chronic HBV infection exhibit a higher miR-221 expression
in tumors compared to patients with either a chronic HCV infection or no hepatitis
infection (FDR = 0.15).
In normals, I found the expression of miR-93 and miR-122 to be significantly
associated with tumor grade. Patients with a low grade tumor generally exhibit
higher expression of miR-93 in normals (FDR = 0.16). Conversely, patients with
low grade tumors exhibit a significantly lower miR-122 expression in normals (FDR
= 0.16).
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Table 3.11: Association between expression of relevant miRNAs and clinical parameters. Significant associations (FDR < 0.2) are highlighted
in bold-face and red. In tumors, miR-122 is significantly associated with AFP levels. Furthermore, miR-221 is associated with age and hepatitis
infection status. In normals, miR-93, and miR-122 were associated with tumor grade.




miR-21 0.69 0.69 0.76 0.57 0.84 0.42 0.89 0.84 0.69 0.49
miR-26a 0.61 0.69 0.76 0.83 0.81 0.89 0.90 1.00 0.71 0.77
miR-93 0.53 0.56 0.29 0.83 0.81 0.89 0.89 0.84 0.28 0.75
miR-122 0.53 0.56 0.80 0.83 0.75 0.89 0.89 0.84 0.34 0.20
miR-130a 0.61 0.56 0.76 0.83 0.81 0.89 0.89 0.84 0.34 0.40
miR-221 0.13 0.61 0.15 0.83 0.81 0.89 0.89 0.84 0.28 0.40
FDR (normals)
miR-21 0.99 0.87 0.95 0.90 0.61 0.62 0.99 0.37 0.58 0.74
miR-26a 0.99 0.87 0.41 0.90 0.40 0.73 0.99 0.81 0.43 0.94
miR-93 0.99 0.69 0.64 0.90 0.40 0.16 0.99 0.32 0.43 0.74
miR-122 0.99 0.87 0.41 0.84 0.70 0.16 0.99 0.81 0.58 0.94
miR-130a 0.99 0.58 0.64 0.90 0.70 0.75 0.99 0.81 0.58 0.94
miR-221 0.99 0.58 0.41 0.26 0.48 0.32 0.99 0.48 0.43 0.94
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Figure 3.18: Significant associations between miRNAs and clinical parameters. (a) MiR-122 expression is higher in tumors of patients with
lower AFP levels; (b) MiR-221 expression is generally higher in tumors of younger patients; (c) Similarly, miR-221 expression is higher in
tumors of patients with chronic HBV infection compared to chronic HCV or no infection; (d) MiR-93 expression is higher in normals of patients
with low grade tumors compared to patients with high grade tumors; (e) Conversely, miR-122 expression is generally higher in normals of
patients with a high grade tumor.
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3.6.3 Differentially expressed microRNA targets associated with
outcome
Similar to the previous analysis of relevant miRNAs, I investigated if differentially
expressed miRNA targets are associated with outcome or other clinical and demo-
graphic variables. Previously, I identified 148 significantly down-regulated likely
targets (FC < 0.66, FDR < 0.2), regulated by at least one up-regulated relevant
miRNA. Similarly, I identified 517 significantly up-regulated likely targets (FC > 1.5,
FDR < 0.2), regulated by at least one down-regulated relevant miRNA. The numbers
are provided in figure 3.11. I associated these targets with OS and DFS in tumors and
normals, using the Cox proportional hazards model where FDR < 0.2 was considered
statistically significant.
In tumors, none of the likely target was significantly associated with OS and
DFS. However, in normals, FADS1 was significantly associated with OS and DFS.
FADS1 exhibits a significantly lower expression in normals compared to tumors (FC
= 1.80 (tumors/normals), FDR = 6.45⇥ 10 6) and is a target of miR-122. The HR
as calculated by the Cox proportional hazards model is 0.34 (FDR = 0.16) for OS
and 0.55 (FDR = 0.08) for DFS. This means that a higher expression of FADS1 in
normals is associated with better outcome.
To visualize the difference in outcome between high and low FADS1 expression in
normals, I split the samples into two groups, using the median expression of FADS1
as a cutoff. I then plotted the survival or disease-free survival probabilities against
time, using a Kaplan-Meier plot (figure 3.19). Clearly, patients with a higher FADS1
expression in the normals show a better OS and DFS.
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(a) Overall survival (p-value = 1.42⇥ 10 3)
























(b) Disease-free survival (p-value = 1.11⇥ 10 4)
Figure 3.19: High FADS1 expression in normals is significantly associated with better overall survival (FDR = 0.16) and better disease-free
survival (FDR = 0.08). (b) The sudden decrease in the high expression group (red line) is due to a tumor recurrence in the patient with the
longest time-to-event.
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3.6.4 Differentially expressed microRNA targets associated with
clinical parameters
I associated expression of differentially expressed likely targets of relevant miRNAs
with clinical and demographic parameters and found their expression in tumors and
normals are significantly associated with encapsulation, stage, grade, gender, AFP
levels, and cirrhosis. I used the Kruskal-Wallis rank sum test to assess the association
of gene expression in tumors and normals with clinical variables. A FDR < 0.2 was
considered statistically significant.
The results are summarized in table 3.12. For each significant association, a
box plot is provided in the appendix figures A.9 and A.9. I found several genes
significantly associated with clinical or demographic factors. Genes in the tumors
showed significant association with stage, grade, and encapsulation. Whereas, genes
in the normals showed significant association with gender, AFP levels, and cirrhosis.
The phenotype is the category in which the gene is activated and therefore expressed
at higher levels. This applies to tumors and normals. For example, expression of
SLC52A2 is higher in high stage tumors and therefore its phenotype is “high stage
(3A, 3B, 4)”.
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Table 3.12: Association of differentially expressed miRNA targets with clinical and
demographic parameters.
Gene Phenotype FDR Target of Tumors/normals
Tumors
SLC52A2 High stage (3A,3B,4) 0.10 miR-122 Up
C8A Low stage (1,2) 0.12 miR-93 Down
IGF1 Low stage (1,2) 0.12 miR-221 Down
SERINC1 Low stage (1,2) 0.12 miR-21 Down
SYNE1 Low stage (1,2) 0.12 miR-93 Down
TLE4 Low stage (1,2) 0.12 miR-93 Down
ABCA8 Low stage (1,2) 0.15 miR-93,miR-221 Down
KDR Low stage (1,2) 0.15 miR-21,miR-221 Down
DPYD Low stage (1,2) 0.17 miR-93 Down
DUSP8 Low stage (1,2) 0.17 miR-21,miR-93 Down
MYO1B Low stage (1,2) 0.17 miR-93 Down
ALDH8A1 Low stage (1,2) 0.18 miR-93 Down
CTBS Low stage (1,2) 0.19 miR-93 Down
KLF9 Low stage (1,2) 0.19 miR-21,miR-93 Down
FMOD Low grade (1,2) 0.11 miR-93 Down
SCARA5 Low grade (1,2) 0.14 miR-93 Down
BHLHE40 Complete encapsulation 0.11 miR-93 Down
FAM134B Complete encapsulation 0.11 miR-221 Down
TIPARP Complete encapsulation 0.11 miR-21,miR-93 Down
CEBPB Complete encapsulation 0.12 miR-93 Down
BBOX1 Complete encapsulation 0.15 miR-221 Down
Normals
DDX3Y Gender (male) 0.05 miR-221 Down
SLC12A7 High AFP (> 400) 0.01 miR-130a Up
NUP43 High AFP (> 400) 0.07 miR-122,miR-130a Up
ABCC5 High AFP (> 400) 0.14 miR-122,miR-130a Up
FANCA High AFP (> 400) 0.14 miR-26a,miR-130a Up
KPNA2 High AFP (> 400) 0.14 miR-26a Up
DLAT No cirrhosis 0.17 miR-26amiR-122 Up




4.1 Basis of this thesis
MiRNAs are critically involved in keeping the balance in gene expression programs
to maintain cellular homeostasis. Therefore, disruption of miRNA expression may
potentially lead to substantial changes in the biology of the cell. There is accumulating
evidence that dys-regulation of miRNAs contributes to the initiation and progression
of various cancers [369]. MiRNAs can act as either oncogenes or tumor suppressors
depending on the genes and cellular function they target. In HCC, studies had
reported that numerous miRNAs are dys-regulated and involved in the modulation of
critical cancer pathways, such as proliferation, migration and invasion, or cell viability
[370]. The evidence available to date strongly suggests that miRNAs are critically
involved in the pathogenesis of HCC. Moreover, in a recent study on mice, Kota et al.
successfully employed miRNA replacement therapy to inhibit tumor growth in HCC
[61]. Even though these are exciting results, we are only beginning to understand
the role of miRNAs in HCC and in cancer in general.
Traditionally, studies had focussed their research on a single miRNA or a small
group of miRNAs in the same family or cluster, and reported one or several of their
direct targets. This approach makes it difficult to gain a comprehensive understanding
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of the role of miRNAs in a specific disease. From target predictions, we know that
each miRNA potentially regulates up to several hundred genes [371]. Therefore, it is
likely that multiple miRNAs control the same or similar cellular function, through
their sets of target genes. These sets of target genes may be overlapping to a greater
or lesser extent. To fully understand the role of miRNAs, in HCC and in cancer in
general, it is crucial to take into consideration as much information as possible.
In this study, I employed a novel and systematic approach to study the role of
miRNAs in HCC. Through integration of whole-genome gene and miRNA expres-
sion profiles of tumors and adjacent non-malignant tissues, combined with target
predictions, I gained a comprehensive understanding of the role of miRNAs in HCC.
4.2 Systematic analysis of microRNAs in HCC
4.2.1 Differential microRNA expression
I compared the expression of 829 mature miRNAs between tumors and normals and
found 26 miRNAs to be significantly down-regulated and 6 miRNAs to be significantly
up-regulated in HCC. Out of the 26 down-regulated miRNAs, 12 are consistent with
previous reports in HCC (cf. table 1.3). These are miR-26a, miR-30a, miR-99a, miR-
122, miR-125a, miR-125b, miR-145, miR-195, miR-199a-3p, miR-199a-5p, miR-223,
and miR-302b.
MiR-130a is down-regulated in HBV-positive compared to HBV-negative HCC cell
lines [345]. This is consistent with the change in expression in the cohort studied
here, where the majority of patients were chronic carriers of HBV. On the other
hand, cisplatin-treatment significantly increases miR-130a expression in patients and
cell lines, associated with RUNX3 down-regulation and consequentially, an increase
in drug-resistance [347]. Taken together, miR-130a acts as a tumor suppressor in
HBV-induced HCC, but over-expression reduces the efficacy of cisplatin-treatment.
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Interestingly, miR-143 and miR-186 are significantly down-regulated in our co-
hort, but were previously found to exhibit oncogenic properties in HCC. MiR-143
is associated with up-regulation in metastatic HBV-positive HCC patients and pro-
motes tumor metastasis in mice [290]. However, a comprehensive study of miRNA
abundance in healthy and diseased liver found miR-143 abundance decreased in
HBV-positive and HCV-positive HCCs compared to adjacent tissues [238]. This is
consistent with my results and suggests that miR-143 is specifically up-regulated in
metastatic HCCs, but not in primary HCCs. On the other hand, miR-186 is involved
in the carcinogenesis of HCC. Its expression levels are increased in cirrhotic liver
and premalignant lesions, but return to normal levels in HCC [299]. About half of
the normal tissue samples in the cohort analyzed here were cirrhotic tissues, which
might explain why miR-186 is down-regulated in our cohort.
Few or no reports are available on other miRNAs that were significantly down-
regulated in our cohort. MiR-33 is activated in aflatoxin B1 associated HCCs and
miR-150 inhibits liver cancer stem cells in human HCC cell lines [372, 373]. MiR-
296, miR-302a, miR-374b, miR-378a, miR-451a, miR-486, miR-922, miR-1224, and
miR-1236 have not been studied previously in the context of HCC.
Out of the six significantly up-regulated miRNAs, miR-21 and miR-221 are fre-
quently over-expressed in solid cancers and associated with oncogenic functions (cf.
table 1.2). In HCC, up-regulation ofmiR-21 andmiR-221 is associated with activation
of proliferation, inhibition of apoptosis, and improved metastatic properties. These
data are summarized in table 1.4.
MiR-93 is over-expressed in HCC and is a member of the miR-25–106b cluster.
All members of the miR-25–106b cluster are attributed with oncogenic functions
[80]. In our cohort, the other members of the cluster, miR-25 and miR-106b, were
also up-regulated, although below statistical significance (miR-25: FC = 1.46, FDR
= 1.05⇥ 10 13; miR-106b: FC = 1.45, FDR = 4.04⇥ 10 10).
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Finally, miR-663a and miR-1469 have not been annotated with an oncogenic or
tumor suppressor role in HCC, nor in other cancers. Recently, miR-1274a was found
to be a misannotated lysine-tRNA rather than a miRNA and was therefore removed
from miRBase [374].
In next step, I narrowed down the list of differentially expressed miRNAs between
tumors and normals to a small set of biologically relevant miRNAs and their likely
targets in HCC.
4.2.2 Integration of gene andmicroRNA expression profiles with
target predictions
It is generally accepted that miRNA target prediction programs overestimate the
number of targets in a specific tissue or condition. The estimated false positive rate
ranges from 20  40% [375]. To reduce the number of false positives, I integrated
target predictions with gene and miRNA expression profiling. Moreover, integration
of all available data would provide a more comprehensive understanding of the
role of miRNAs in HCC. Through expression patterns observed in gene and miRNA
expression profiles from HCC patients, I identified differentially expressed miRNAs
that regulate significantly more predicted targets than expected by chance. At the
same time, I reduced the number of false positive target genes.
Recently, a similar approach was employed for systematic analysis of the role
of miRNAs in breast cancer [376]. Rinaldis et al. used a method developed for
integration of gene expression profiles with miRNA target predictions and applied
it to gene as well as miRNA expression profiles. The authors compared the set of
predicted miRNA targets that showed high correlation in expression with the miRNA.
The correlation was calculated across 173 primary tumor samples. Using Fisher’s
exact test, the authors evaluated enrichment of predicted targets in highly correlated
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gene transcripts. Samples were split into two groups using a cutoff (rho = 0.3).
However, only a single cluster of miRNAs showed significant enrichment.
In my opinion, the approach proposed in this thesis provides two important
advantages over the method employed by Rinaldis et al. Firstly, I found that the
correlation across tumors and normals is more suitable to identify targets that are
potentially regulated by miRNAs, assuming that matched normals are available.
Furthermore, the statistical power is increased through consideration of twice the
number of data points. In the case of our cohort, the correlation across tumors
takes 100 data points into consideration, whereas the correlation across tumors and
normals takes 200 data points into consideration. Secondly, the approach employed
here makes use the strength of miRNA regulation of each gene, which is achieved
using GSEA instead of Fisher’s exact test. In other words, a gene with a correlation
coefficient of rho =  0.5 contributes more to the enrichment score than a gene with
a correlation coefficient of rho =  0.3. This information is not taken into account
when using Fisher’s exact test. Also, it is not clear what value should be used as a
cutoff on correlation. Rinaldis et al. used rho <  0.3 to distinguish between genes
that are regulated and non-regulated by a specific miRNA. On the other hand, GSEA
takes all the data into consideration and derives a cutoff from the distribution of
negative correlation coefficients.
The main effect of miRNA target regulation leads to a decrease of the mRNA levels,
which is measurable using expression profiling. MiRNAs control gene expression
through translational repression as well as degradation of the target mRNA. Both
mechanisms possibly lead to a decrease of protein levels. However, only target mRNA
degradation is measurable using gene expression profiling, because it leads to a
reduction in the number of gene transcripts. In this analysis, I used the correlation
between gene and miRNA expression as a measure of target regulation. However, this
approach only accounts for target mRNA degradation, but not translational repression
with unchanged mRNA levels. Guo et al. studied the contributions of translational
repression and mRNA degradation on protein production. They found that lowered
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mRNA levels account for more than 84% of the reduction in protein levels [377]. As
a consequence, it seems reasonable to assume that a strong correlation in expression
between a gene and a miRNA, as depicted in figure 3.8, indicates a miRNA-target-
interaction that results in a substantial difference in protein levels between tumors
and normals. And although I am aware that through the proposed approach a few
specific mRNA-miRNA interactions might be missed due to their lack of correlation in
expression, I think that this does not substantially affect the overall biological trends
observed.
4.2.3 Effects of microRNA dys-regulation on cellular pathways
I found targets of relevant miRNAs enriched in critical cellular pathways, specifically
pathways related to metabolism, immune system response, or genetic information
processing. These results suggest that miRNA dys-regulation contributes substantially
to the formation and progression of HCC.
Targets of up-regulated relevant miRNAs are involved in metabolism, specifi-
cally amino acid, carbohydrate, and lipid metabolism. MiR-21, miR-93, and miR-
221, which are up-regulated in HCC, have previously been implicated in lipid
metabolism [378–381]. My results suggest that metabolic pathways, specifically
energy metabolism, an intrinsic function of the liver, is regulated by these miRNAs.
This function is potentially suppressed or modulated in HCC as a consequence of
miRNA over-expression in tumors. I hypothesize that metabolic processes which are
not essential for the viability of malignant cells are reduced in favor of processes that
contribute to the formation and progression of HCC.
Furthermore, processes related to the immune system are enriched in targets of
up-regulated relevant miRNAs, miR-21, miR-93, and miR-221, suggesting that these
miRNAs contribute to the HCC carcinogenesis through modulation of the immune
system response. Targets of up-regulated relevant miRNAs are involved in several
processes related to the immune system. For example, toll-like receptor signaling
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is enriched in targets of all three up-regulated relevant miRNAs. Toll-like receptors
play an important role in the innate host defence mechanisms [382]. They recognize
pathogenic agents, such as viral double-stranded RNA, and activate an appropriate
immune response [383].
Cell growth and death pathways are enriched in targets of up-regulated as well
as in targets of down-regulated relevant miRNAs. More specifically, targets of up-
regulated relevant miRNAs, which are frequently down-regulated in HCC, are associ-
ated with apoptosis. On the other hand, targets of down-regulated relevant miRNAs,
which are frequently up-regulated in HCC, are associated with cell cycle. Consis-
tently, up-regulation of miR-21, miR-93, and miR-221 was previously associated with
apoptosis inhibition through regulation of PTEN, PDCD4, and TIMP [80, 114, 281].
Here, I found that down-regulation of miR-26a, miR-122, and miR-130a is associated
with cell cycle activation. This is consistent with previous reports which showed that
miR-26a inhibits G1/S transition through regulation of CDK6 and CCNE1 [174], and
that miR-122 is involved in the control of cell growth and replication in a mouse
model [191]. In addition, I found that targets of all six relevant miRNAs are involved
in p53 signaling. It is well known that p53 signaling mediates apoptosis and inhibits
cell-cycle progression in response to cellular stress signals [384]. The findings in this
thesis support these previous observations and suggest that processes related to cell
growth and death are regulated by the six dys-regulated relevant miRNAs. Taken
together, the results strongly suggest that relevant miRNAs enhance cell viability and
promote cell cycle through regulation of cell growth and death pathways on different
levels, possibly leading to a more systemic and robust regulatory effect.
Enrichment of miRNA targets in processes related to DNA replication and repair,
transcription, and protein synthesis is likely a consequence of the activation of the cell
cycle in cancer cells. I previously discussed that targets of down-regulated relevant
miRNAs are involved in cell cycle. These targets tend to be over-expressed in HCC, a
consequence of miRNA dys-regulation. The same sets of target genes also showed
enrichment in DNA replication and repair, a group of processes which are associ-
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ated with cell cycle. Furthermore, miRNA targets are also significantly involved in
transcription, nucleotide metabolism, and protein synthesis and degradation. These
results suggest that down-regulated relevant miRNAs control specific transcription
and translation pathways. An increase in protein turnover is a requirement for ef-
ficient cell cycle progression in tumor cells [385]. In summary, these findings not
only support an important cell-cycle regulatory function of miR-26a, miR-122, and
miR-130a, but also reinforce the observation that down-regulated relevant miRNAs
are involved in all aspects of the cell cycle control, from protein synthesis to transition
through cell-cycle checkpoints.
4.2.4 Collaborative strategy of dys-regulated microRNAs
The modulation of essentially the same important biological pathways by relevant
miRNAs through largely distinct sets of target genes suggests a collaborative strategy
of miRNA regulation. Up-regulated relevant miRNAs modulate essentially the same
biological themes, that is pathways related to metabolism, immune system response,
and cell growth and death. Similarly, down-regulated relevant miRNAs modulate
essentially the same biological themes, that is pathways related to genetic information
processing, cell growth and death, and nucleotide metabolism. However, the set of
target genes regulated by each relevant miRNA is substantially different, as illustrated
in figures 3.11 and A.8. As a consequence, I think that relevant miRNAs coordinately
regulate the same biological pathways, but exert their control on different levels.
A coordinated regulation of important pathways by multiple miRNAs may possibly
result in a more robust and comprehensive regulatory effect, suggesting a certain
level of redundancy in the system.
None two relevant miRNAs are members of the same cluster or family of miRNAs
and are likely independently regulated. Traditionally, miRNAs are studied either
individually or in clusters or families. Due to their proximity or sequence similarity,
miRNA clusters or families tend to exhibit similar expression patterns or regulate
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a similar set of targets. As a consequence, several members of a cluster or family
might be coordinately dys-regulated in cancer and/or involved in the regulation of
the same biological functions. In this study, I identified six differentially expressed
miRNAs that are critically involved in pathways associated with cancer. Therefore,
these miRNAs likely contribute to the formation and progression of HCC. Within
these six relevant miRNAs, no two miRNAs are members of the same cluster or family.
I also assessed their pairwise correlation, which might suggest a co-regulation of their
expression in the liver. Only two pairs of miRNAs were moderately correlated, namely
miR-26a/miR-130a and miR-93/miR-221, with a correlation coefficient  0.6. Thus,
this evidence indicates that all six relevant miRNAs are independently regulated in
liver cells. Nevertheless, my results strongly suggest that these miRNAs modulate
essentially the same biological pathways through a largely unique set of target genes.
As a consequence, I think that groups of relevant miRNAs not only coordinately, but
also independently regulate the same biological themes. To my knowledge, this is the
first study that identified “non-related” miRNAs to coordinately modulate important
cellular pathways.
Overall, these findings suggest that a treatment strategy involving multiple miR-
NAs might lead to a more robust response than when a single miRNA is targeted only.
Through miRNA replacement therapy in mice, Kota et al. showed that systemic ad-
ministration of miR-26a inhibits cancer cell proliferation and induces tumor-specific
apoptosis [61]. Consistently, I found that miR-26a is down-regulated in HCC and
its targets are significantly associated with cell cycle. Similarly, targets of miR-122
and miR-130a are also significantly associated with cell cycle. Consequentially, I
think that replacement therapy with a combination of these down-regulated miRNAs,
possibly combined with inhibition of one or several up-regulated relevant miRNAs,
might provide further improvements to the efficacy of a treatment strategy based on
miRNAs in HCC.
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4.2.5 Key genes involved in microRNA-regulated pathways
Gene network analysis revealed several key genes critically involved in the pathways
modulated by relevant miRNAs. We established gene networks from differentially
expressed miRNA targets involved in similar biological pathways, using the IPA
knowledge base and network generation algorithm. Interestingly, the genes with the
highest connectivity in each network are frequently associated with cancer, namely
IL6, CXCL8, TP53, TP73, PTEN, and AKT.
Pro-inflammatory genes IL6 and CXCL8 (or IL8) are highly connected in the
metabolic network, which was established from relevant targets of miR-21, miR-
93, and miR-221. Both genes are down-regulated in tumors compared to normals
and their expression is directly controlled by miR-93. IL6 levels are elevated in
pre-malignant lesions and HCC progenitor cells [386]. Consequentially, we think
that IL6 transcript levels are decreased in fully-malignant HCC cells compared to
non-malignant tissues, as a result of miR-93 over-expression. Besides its involvement
in metabolism, chemokine CXCL8 also exhibits a high connectivity in the network
established from genes involved in immune-system-response and inflammatory path-
ways. In addition, TP53 is also a key gene in these pathways, even though it is
not a direct target of miR-21, miR-93, or miR-221. Taken together, miRNA-induced
down-regulation of IL6 and CXCL8 in HCC potentially perturbs intrinsic metabolic
pathways of liver cells, and at the same time leads to a survival advantage through
evasion of the immune system response [387, 388].
Unsurprisingly, TP53 and TP73 are key genes involved in cell cycle and apoptosis.
TP53 and TP73 are well studied tumor suppressor genes in the p53 signaling pathway
and inducers of apoptosis [389]. As discussed previously, pathway enrichment
analysis revealed that targets of both up-regulated and down-regulated relevant
miRNAs are involved in p53 signaling, associated with the modulation of apoptosis
and cell cycle (table 3.9). Therefore, it would almost be expected that TP53 and
the TP53 homologue TP73 are at the center of the cell growth and death network.
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Several other genes in the network provide further evidence that apoptosis is indeed
suppressed in tumors. For example, LATS2, a target ofmiR-93 and significantly down-
regulated in HCC, is a promoter of TP53-mediated apoptosis [390]. In summary, we
found that tumor suppressors TP53 and TP73 are critically involved in the regulation
of cell cycle and apoptosis pathways, down-stream of miRNAs dys-regulated in HCC.
PTEN and AKT are key genes involved in DNA replication and repair, transcription,
and DNA metabolism, suggesting that they are indirectly regulated by miRNAs and
critically involved in the cell cycle in HCC.MiR-26a andmiR-122 have previously been
involved in the regulation of the AKT signaling pathway in HCC. More specifically,
miRNA-induced down-regulation of VEGFA and AKT3 is associated with inhibition of
angiogenesis, cell migration, proliferation, and induction of apoptosis [391, 392].
However, based on our data, we think that PTEN and AKT are not directly regulated
by miR-26a, miR-122, or miR-130a, but through the EZH2 oncogene, for example.
Interestingly, apoptosis inhibitor EZH2 is a known target of miR-26a in breast, head
and neck, and blood cancers, but there are no reports in HCC [85, 86, 393]. There-
fore, down-regulation of miR-26a, miR-122, and miR-130a disrupts AKT signaling
through dys-regulation of their indirect targets AKT and PTEN, possibly contributing
to enhanced cell survival in HCC.
In summary, our findings suggest that IL6, CXCL8, TP53, TP73, PTEN, and AKT are
direct or indirect miRNA targets, which are critically involved in important pathways
dys-regulated in HCC. Since these genes are at the center of pathways dys-regulated
in cancer, they are potential targets for therapeutic interventions. However, further
investigations will be necessary to fully understand their role in HCC and assess their
possible therapeutic potential.
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4.3 Diagnostic and prognostic potential of microRNAs
and their targets
MiRNAs are promising targets for diagnostic or prognostic applications. Several
reports associated miRNA expression with outcome in HCC, such as expression of
miR-101, miR-124, or miR-155 [185, 203, 293]. Moreover, several studies success-
fully showed a therapeutic advantage of miRNA antagonists, inhibiting miRNAs that
acquire a gain of function, and miRNA mimics, restoring miRNAs that show a loss of
function, in mice [61, 394]. I evaluated the diagnostic and prognostic potential of
relevant miRNAs and their differentially expressed likely targets, through correla-
tion of their expression in tumors and normals with outcome and other clinical or
demographic parameters.
Survival analysis of relevant miRNA in tumors and normals revealed no significant
association with overall or disease-free survival. Several relevant miRNAs have
previously been associated with outcome. Li et al. found that miR-130a is down-
regulated in HCC and that patients with lower miRNA expression showed significantly
poorer outcome [346]. My analysis suggests that higher miR-130a expression in
tumors is associated with poorer disease-free survival. However, this result was
not statistically significant (HR = 1.62, FDR = 0.37). Similarly, Gramantieri et
al. reported that tumors with higher miR-221 levels exhibit a significantly higher
recurrence rate [308]. I did not investigate recurrence alone, only in combination
with death (DFS) because of the small number of recurrence events. The analysis
did not reveal a significant association between miR-221 expression and outcome
(OS: FDR = 0.66; DFS: FDR = 0.86).
There are several possible reasons that our data set did not show any significant
associations between miRNA expression and outcome. The relatively small number
of events can be explained by the short duration of the study, the longest follow-up
was < 7 years. Another limitation is that the cohort was treated as a homogeneous
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group, even though tumor subtypes were reported in HCC [395]. However, these
subtypes are based on gene expression and might not be distinguishable using miRNA
expression profiles.
I also correlated differentially expressed miRNA targets with patient outcome.
FADS1, a target of miR-122, showed significant association with OS and DFS in
normals and might serve as a prognostic marker. The FADS1 gene is involved in
the metabolism of polyunsaturated fatty acids [396]. Moreover, high FADS1 levels
are associated with resistance to steatosis, a risk factor for fibrosis and cirrhosis
[397]. Therefore, FADS1 expression levels in non-malignant tissue might serve as
a prognostic marker for HCC patients. As FADS1 is a target of miR-122, I might
expect a similar trend between miR-122 and outcome. However, this was not the
case, possibly due to the limited number of events observed during the time of the
study.
Several relevant miRNAs and some of their differentially expressed targets showed
significant association with clinical parameters, such as hepatitis infection, AFP levels,
tumor stage, or histological grade. These miRNAs or genes might serve as diagnostic
or prognostic markers. MiR-221 expression in tumors is significantly higher in patients
which were diagnosed at an younger age (age  60). Moreover, miR-221 expression
in tumors is also significantly higher in patients with chronic HBV infection compared
to non-HBV-associated HCC. A small but significant correlation between age and HBV
status was observed (P-value: 0.03, Fisher’s exact test). Even though the mechanism
remains unclear, it is unlikely that the change in miR-221 expression levels is induced
by the HBV protein X [342]. Nevertheless, patients with an underlying chronic HBV
infection might exhibit an enhanced benefit from therapeutic inhibition of miR-221
compared to patients with non-HBV-associated HCC. MiR-93 and miR-122 expression
in normals is significantly associated with grade of tumor. Specifically, high-grade
tumors exhibit lower miR-93 expression and higher miR-122 expression in normals.
Lower miR-93 expression, higher miR-122 expression respectively, might correlate
with a stronger fold difference between tumors compared to normals, which in turn
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leads to a more potent perturbation of gene expression, perhaps resulting in a more
aggressive cancer. Indeed, low miR-93 and high miR-122 expression in normals is
significantly associated with a high fold change (miR-93: p-value = 0.0016; miR-122:
p-value < 10 7). These findings suggest that miR-93 and miR-122 expression in
normals might serve as independent prognostic factors in HCC.
I also found that the expression of several differentially expressed miRNA targets
to correlate with gender, tumor stage, tumor grade, encapsulation, AFP levels, or
cirrhosis. For example, expression of DUSP8, a target of miR-21 and miR-93, is
significantly associated with tumor stage. Low-stage tumors (stages 1 and 2) exhibit
significantly higher DUSP8 expression compared to high-stage tumors (stages 3A, 3B,
and 4). DUSP8 is a negative regulator of MAPK signaling, a pathway activated by
growth factors and cellular stress signals [398]. Further investigations are necessary
to better understand if and how these differentially expressed miRNA targets might
serve as diagnostic or prognostic markers.
4.4 Conclusion and future perspectives
This thesis provided new insights into the role of miRNAs in HCC, through integration
and systematic analysis of in silico miRNA target predictions and whole-genome gene
and miRNA expression profiling of tissues from HCC patients.
The results strongly suggest that six differentially expressed miRNAs play an
important role in HCC, namely miR-21, miR-26a, miR-93, miR-122, miR-130a, and
miR-221. These miRNAs are important for mainly two reasons: 1) Dys-regulation of
these miRNAs is significantly associated with differential expression of their predicted
targets; and 2) their likely targets are involved in critical cellular pathways frequently
dys-regulated in cancer, such as metabolism or cell cycle. Strikingly, I found that
miRNAs regulate the same pathways through largely distinct sets of target genes,
providing evidence that they coordinately regulate cellular functions. I think that this
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behavior results in a more robust and comprehensive regulatory effect, suggesting
that miRNA regulatory processes are built with redundancy. As a direct and far-
reaching consequence, miRNA-based therapy might be more effective when targeting
several miRNAs. This is an important factor to be considered when designing miRNA-
based therapeutic applications. In addition, although the findings in this thesis only
apply to the liver and HCC, similar mechanisms may exist in other cancers and
diseases in general.
I also identified several direct or indirect miRNA targets that are critically involved
in these miRNA-modulated pathways. Interestingly, they are either well-studied tu-
mor suppressors or otherwise associated with cancer. However, further investigations
will be necessary to elucidate their function in these networks and more generally
how dys-regulation of these genes contributes to HCC. For example, a good place
to start would be molecules for which antibodies are either approved or studied in
clinical trials.
The data used in this thesis are expression profiles of HCC patients. With this
data, it was not possible to study possible causes for miRNA dys-regulation. Several
causes might contribute to the dys-regulation in miRNA expression observed in HCCs
compared to non-tumorous tissues. For example, copy number variations might lead
to an increase or decrease in copies of one or more miRNAs, possibly affecting their
expression. Moreover, polymorphisms or structural variations in the miRNAs or their
regulatory regions may also affect their transcription rate. However, to study these
DNA changes, one would have to sequence candidate sites in the respective samples
using DNA-sequencing technology.
Moving forward, miRNAs will continue to draw great interest. Previous work
and this thesis have shown that miRNAs play an important role in HCC and in cancer
in general. Nevertheless, the field of small non-coding RNAs is fairly recent and we
are only beginning to understand the role of miRNAs in cancer and to explore their
therapeutic potential. Replacement and inhibition therapy of individual miRNAs had
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been shown to have a beneficial effect in mice. The next steps will be to use these
findings and the technologies emerging from research and move them forward in
order to eventually bring them to the clinics to the benefit of patients.
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(d) Normals after normalization
Figure A.1: Intensity distribution of tumor and normal gene expression profiles
before and after normalization.
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(d) Normals after normalization
Figure A.2: Intensity distribution of tumor and normal miRNA expression profiles
before and after normalization.
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Heatmap of differentially expressed miRNAs
Figure A.3: Heatmap of differentially expressed miRNAs between tumors and nor-
mals.
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Figure A.4: Expression of miR-93 and the most likely targets.
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GSEA enrichment plots ofmiRNAswith significance against
at least one target prediction programs
(a) miR-26a/MiRanda (b) miR-26a/MirTarget2
(c) miR-122/MiRanda (d) miR-122/MirTarget2
(e) miR-130a/MiRanda (f) miR-130a/MirTarget2
Figure A.5: Down-regulated miRNAs with significant enrichment in both target
prediction programs (FDR < 10 3).
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(a) miR-21/MiRanda (b) miR-21/MirTarget2
(c) miR-93/MiRanda (d) miR-93/MirTarget2
(e) miR-221/MiRanda (f) miR-221/MirTarget2
Figure A.6: Up-regulated miRNAs with significant enrichment in both target predic-
tion programs (FDR < 10 3).
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(a) miR-30a/MiRanda (b) miR-30a/MirTarget2
(c) miR-195/MiRanda (d) miR-195/MirTarget2
(e) miR-663a/MiRanda (f) miR-663a/MirTarget2
Figure A.7: Up- or down-regulated miRNAs with significant enrichment in only one
target prediction program (FDR < 10 3).
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Shared likely targets of relevant miRNAs






















Figure A.8: Shared likely targets of relevant miRNAs. Less likely targets are shared
compared to the number of likely targets unique to each up-regulated relevant miRNA.
Similarly, less likely targets are shared compared to the number of likely target unique
to each down-regulated relevant miRNA.
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Shared KEGG pathways enriched in targets of down-/up-regulated miRNAs
Table A.1: KEGG pathways enriched in targets of down-regulated miRNAs. Only pathways with a FDR < 0.2 in targets of at least one
down-regulated relevant miRNA are listed.
KEGG Pathway Pathway Group miR-26a miR-122 miR-130a
DNA replication Replication and repair 2.74E-03 6.64E-02 <1E-04
Homologous recombination Replication and repair 4.55E-03 1.04E-01 2.62E-02
Mismatch repair Replication and repair 5.16E-03 – 6.89E-02
Protein export Membrane transport 7.74E-03 1.02E-01 2.05E-02
Spliceosome Transcription 1.38E-02 1.12E-01 2.39E-02
Pyrimidine metabolism Nucleotide metabolism 1.80E-02 1.60E-01 2.56E-02
Nucleotide excision repair Replication and repair 2.29E-02 – –
Cell cycle Cell growth and death 2.43E-02 1.68E-01 2.99E-02
RNA degradation Folding, sorting and degradation 3.62E-02 1.10E-01 1.24E-01
RNA polymerase Transcription 6.03E-02 – –
Base excision repair Replication and repair 7.27E-02 – 1.54E-01
P53 signaling pathway Cell growth and death 8.89E-02 1.67E-01 1.04E-01
Steroid biosynthesis Lipid metabolism 1.05E-01 – –
Purine metabolism Nucleotide metabolism 1.05E-01 – 1.91E-01
Glycosylphosphatidylinositol GPI anchor
biosynthesis Glycan biosynthesis and metabolism 1.39E-01 1.34E-01 1.19E-01
Ubiquitin mediated proteolysis Folding, sorting and degradation 1.69E-01 – –
Ribosome Translation 1.82E-01 8.11E-02 –
Aminoacyl tRNA biosynthesis Translation – 1.52E-01 –
Selenoamino acid metabolism Metabolism of other amino acids – 1.81E-01 –
Basal transcription factors Transcription – – 1.52E-01
Proteasome Folding, sorting and degradation – – 1.80E-01
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Table A.2: KEGG pathways enriched in targets of up-regulated miRNAs. Only pathways with a FDR< 0.2 in targets of at least one up-regulated
relevant miRNA are listed.
KEGG pathway Pathway group miR-21 miR-93 miR-221
Complement and coagulation cascades Immune system <1E-04 3.09E-04 <1E-04
Fatty acid metabolism Lipid metabolism <1E-04 <1E-04 <1E-04
Retinol metabolism Metabolism of cofactors and vitamins <1E-04 9.25E-04 1.35E-03
Arginine and proline metabolism Amino acid metabolism 8.52E-05 1.13E-02 1.65E-02
Beta alanine metabolism Metabolism of other amino acids 9.37E-05 1.86E-04 1.97E-03
Primary bile acid biosynthesis Lipid metabolism 1.04E-04 3.69E-02 6.42E-03
Propanoate metabolism Carbohydrate metabolism 1.17E-04 5.28E-04 4.71E-04
Drug metabolism – cytochrome p450 Xenobiotics biodegradation and metabolism 1.34E-04 <1E-04 4.69E-04
Valine, leucine and isoleucine degradation Amino acid metabolism 1.56E-04 <1E-04 5.65E-04
Ascorbate and aldarate metabolism Carbohydrate metabolism 1.56E-04 2.10E-03 1.63E-02
Drug metabolism – other enzymes Xenobiotics biodegradation and metabolism 1.87E-04 <1E-04 4.70E-04
Glycine, serine and threonine metabolism Amino acid metabolism 2.34E-04 1.93E-03 <1E-04
Pentose and glucuronate interconversions Carbohydrate metabolism 7.23E-04 8.22E-02 1.27E-01
Metabolism of xenobiotics by cytochrome p450 Xenobiotics biodegradation and metabolism 8.05E-04 1.96E-03 4.02E-03
Tryptophan metabolism Amino acid metabolism 9.41E-04 2.25E-03 5.37E-04
P53 signaling pathway Cell growth and death 1.12E-03 3.60E-02 1.43E-02
Butanoate metabolism Carbohydrate metabolism 1.22E-03 1.85E-03 2.02E-02
Histidine metabolism Amino acid metabolism 1.46E-03 4.62E-04 6.27E-03
Peroxisome Transport and catabolism 1.73E-03 7.58E-02 9.98E-03
Steroid hormone biosynthesis Lipid metabolism 2.02E-03 1.19E-02 1.01E-02
Citrate cycle (TCA cycle) Carbohydrate metabolism 2.19E-03 5.89E-02 3.50E-03
PPAR signaling pathway Endocrine system 2.39E-03 2.59E-02 1.07E-02
Continued on next page
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Table A.2 – Continued from previous page
KEGG pathway Pathway group miR-21 miR-93 miR-221
Linoleic acid metabolism Lipid metabolism 3.45E-03 1.14E-02 2.86E-02
Alanine, aspartate and glutamate metabolism Amino acid metabolism 3.47E-03 1.16E-02 2.04E-03
Tyrosine metabolism Amino acid metabolism 4.32E-03 1.30E-02 4.97E-02
Nitrogen metabolism Energy metabolism 5.21E-03 4.96E-02 2.09E-02
Lysine degradation Amino acid metabolism 5.33E-03 3.74E-02 1.20E-02
Pyruvate metabolism Carbohydrate metabolism 7.45E-03 1.21E-02 8.35E-02
Intestinal immune network for IgA production Immune system 9.43E-03 5.19E-03 1.08E-01
Cysteine and methionine metabolism Amino acid metabolism 9.87E-03 1.35E-02 8.66E-03
Starch and sucrose metabolism Carbohydrate metabolism 2.00E-02 2.21E-03 6.31E-03
Adipocytokine signaling pathway Endocrine system 2.33E-02 1.39E-02 1.77E-02
Nicotinate and nicotinamide metabolism Metabolism of cofactors and vitamins 3.29E-02 2.58E-02 1.24E-01
TGF-beta signaling pathway Signal transduction 4.24E-02 8.41E-02 6.06E-02
Biosynthesis of unsaturated fatty acids Lipid metabolism 4.28E-02 – –
Pentose phosphate pathway Carbohydrate metabolism 4.32E-02 – –
Hematopoietic cell lineage Immune system 4.36E-02 2.10E-03 9.66E-02
B cell receptor signaling pathway Immune system 4.87E-02 1.76E-03 7.80E-03
Fc epsilon RI signaling pathway Immune system 5.17E-02 3.61E-02 1.28E-01
Cell adhesion molecules (CAMs) Signaling Molecules and interaction 5.35E-02 1.68E-02 1.01E-01
ECM-receptor interaction Signaling molecules and interaction 5.83E-02 1.20E-01 –
Glycolysis gluconeogenesis Carbohydrate metabolism 6.77E-02 1.09E-02 1.08E-01
Vascular smooth muscle contraction Circulatory system 7.11E-02 1.28E-01 1.74E-01
Porphyrin and chlorophyll metabolism Metabolism of cofactors and vitamins 7.37E-02 – –
Apoptosis Cell growth and death 7.48E-02 8.52E-02 1.15E-01
Cytokine cytokine receptor interaction Signaling molecules and interaction 7.69E-02 0.07571611 –
Continued on next page
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Table A.2 – Continued from previous page
KEGG pathway Pathway group miR-21 miR-93 miR-221
Natural killer cell mediated cytotoxicity Immune system 7.81E-02 3.01E-02 1.31E-01
Jak-STAT signaling pathway Signal transduction 8.55E-02 1.01E-01 1.46E-01
Arachidonic acid metabolism Lipid metabolism 8.55E-02 8.53E-02 1.10E-01
Glycerolipid metabolism Lipid metabolism 8.79E-02 – –
Chemokine signaling pathway Immune system 9.00E-02 3.72E-02 1.70E-01
GnRH signaling pathway Endocrine system 9.87E-02 – –
Toll-like receptor signaling pathway Immune system 1.19E-01 9.85E-02 1.22E-01
VEGF signaling pathway Signal transduction 1.83E-01 1.97E-01 –
Neurotrophin signaling pathway Nervous system 1.92E-01 – 1.62E-01
T -cell receptor signaling pathway Immune system – 3.013E-02 9.13E-02
Axon guidance Development – 8.60E-02 –
Fc gamma R-mediated phagocytosis Immune system – 8.48E-02 –
Gap junction Cell communication – 8.34E-02 1.06E-01
Phenylalanine metabolism Amino acid metabolism – 1.11E-01 1.16E-02
Focal adhesion Cell communication – 1.22E-01 2.00E-01
Leukocyte transendothelial migration Immune system – 1.21E-01 1.43E-01
Dorso ventral axis formation Development – 1.21E-01 2.10E-02
MAPK signaling pathway Signal transduction – 1.30E-01 1.93E-01
NOD-like receptor signaling pathway Immune system – 1.97E-01 –
Glycosphingolipid biosynthesis – lacto and
neolacto series Glycan biosynthesis and metabolism – – 1.29E-01
Galactose metabolism Carbohydrate metabolism – – 1.32E-01
Cytosolic dna sensing pathway Immune system – – 1.32E-01
Insulin signaling pathway Endocrine system – – 1.58E-01
Continued on next page
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Table A.2 – Continued from previous page
KEGG pathway Pathway group miR-21 miR-93 miR-221
ABC transporters Membrane transport – – 1.72E-01
mTOR signaling pathway Signal transduction – – 1.99E-01
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Table A.3: Shared GO pathways enriched in targets of down-regulated miRNAs.
Only pathways with a FDR < 0.2 in targets of all three relevant down-regulated
miRNAs are listed.
GO pathway miR-26a miR-122 miR-130a
RNA splicing via transesterification reactions 1.07E-02 1.91E-01 2.78E-02
RNA splicing 2.19E-02 1.37E-01 3.01E-02
Cell cycle checkpoint (GO0000075) 2.27E-02 1.67E-01 5.60E-02
MRNA metabolic process 2.81E-02 1.19E-01 3.30E-02
M phase 3.91E-02 1.87E-01 4.84E-02
Cell cycle process 3.65E-02 1.40E-01 3.11E-02
RNA processing 3.50E-02 1.83E-01 5.99E-02
DNA replication 3.63E-02 1.99E-01 6.23E-02
Mitosis 4.83E-02 1.26E-01 2.24E-02
Protein ubiquitination 4.57E-02 1.79E-01 2.14E-02
DNA dependent DNA replication 4.38E-02 1.90E-01 1.01E-01
Microtubule cytoskeleton organization and biogenesis 4.15E-02 1.85E-01 3.73E-02
Mitotic cell cycle 3.87E-02 1.04E-01 2.19E-02
Cell cycle phase 3.91E-02 1.77E-01 3.27E-02
Protein modification by small protein conjugation 5.04E-02 1.76E-01 4.46E-02
Organelle localization 5.63E-02 1.72E-01 2.95E-02
Regulation of DNA metabolic process 8.98E-02 1.97E-01 1.50E-01
Cell cycle (GO0007049) 9.24E-02 1.93E-01 9.32E-02
DNA integrity checkpoint 9.99E-02 1.83E-01 6.03E-02
Protein folding 1.29E-01 1.82E-01 7.78E-02
Mitotic cell cycle checkpoint 1.85E-01 1.63E-01 2.46E-02
DNA damage response signal transduction 1.93E-01 1.86E-01 1.39E-01
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Table A.4: Shared GO pathways enriched in targets of up-regulated miRNAs. Only
pathways with a FDR < 0.2 in targets of all three relevant up-regulated miRNAs are
listed.
GO pathway miR-21 miR-93 miR-221
Hemostasis 1.75E-02 1.49E-01 1.63E-01
Amine catabolic process 9.42E-03 1.92E-01 1.30E-01
Amino acid catabolic process 8.04E-03 1.80E-01 1.37E-01
Blood coagulation 1.36E-02 1.36E-01 1.39E-01
Organic acid metabolic process 1.21E-02 1.07E-01 8.76E-02
Carboxylic acid metabolic process 1.58E-02 1.09E-01 1.15E-01
Coagulation 1.41E-02 1.42E-01 1.42E-01
Wound healing 1.88E-02 1.49E-01 1.64E-01
Monocarboxylic acid metabolic process 2.46E-02 1.13E-01 9.80E-02
Amino acid metabolic process 2.33E-02 1.36E-01 1.55E-01
Lipid catabolic process 2.51E-02 7.78E-02 1.16E-01
Lipid transport 3.18E-02 6.63E-02 1.23E-01
Response to wounding 3.02E-02 6.92E-02 9.91E-02
Amino acid and derivative metabolic process 3.48E-02 1.50E-01 1.78E-01
Cellular lipid catabolic process 4.13E-02 6.13E-02 1.09E-01
Regulation of angiogenesis 4.85E-02 1.78E-01 1.41E-01
Response to external stimulus 6.54E-02 8.73E-02 1.80E-01
Inflammatory response 6.73E-02 4.85E-02 1.02E-01
Actin polymerization and/or depolymerization 6.97E-02 1.57E-01 1.47E-01
Humoral immune response 9.24E-02 1.02E-01 1.83E-01
Immune response 1.03E-01 6.52E-02 1.78E-01
Response to other organism 1.08E-01 1.32E-01 1.79E-01
Defense response 1.13E-01 5.88E-02 1.35E-01
Viral infectious cycle 1.31E-01 1.82E-02 1.47E-01
Anatomical structure formation 1.46E-01 1.88E-01 1.86E-01
Immune system process 1.62E-01 1.04E-01 1.76E-01
Endosome transport 1.61E-01 5.62E-02 1.78E-01
Regulation of phosphorylation 1.89E-01 1.04E-01 1.74E-01
Positive regulation of phosphorylation 1.95E-01 7.84E-02 1.77E-01
Regulation of cyclin dependent protein kinase activity 1.95E-01 1.58E-02 1.89E-01
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Figure A.10: MiRNA targets association with clinical features.
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